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Abstract 
Background: It can be difficult for patients who do not have prescription medication cost 
coverage to adhere to their medications. No previous study has examined the time-trend and 
impact of absence of coverage on adherence to oral diabetes and hypertension medications in 
Canada.  
Methods: Using data from the Canadian Community Health Survey cycles 2007, 2008, 2013, 
and 2014, I included individuals from participating provinces that opted to include questions 
about coverage (Ontario and New Brunswick). Included adults had either hypertension or 
diabetes and answered questions on both coverage and adherence to medications. A 
multivariate-adjusted logistic regression model was fitted to estimate the odds of non-
adherence depending on coverage. I adjusted for confounding variables including demographic 
factors (socioeconomic status; age, education, sex, province of residence), and health system 
and behaviour variables (such as smoking, having a regular doctor, not receiving a flu shot, as 
well as having additional comorbidities). 
Results: The pseudo-cohort included 23,215 individuals. The weighted average age was 60 
years. 20% of participants reported absence of coverage. This percentage increased slightly 
over the study period. Patients with no prescription medication coverage were at 23% higher 
odds of not adhering to their medication (adjusted odds ratio (OR) 0.77; 95% CI (Confidence 
Interval) 0.657 - 0.911). Subgroup analysis revealed that patients aged less than 65 years, lived 
in Ontario, and had a middle-income were also at a statistically significant lower odd for 
adherence with absence of insurance.  
Conclusion: Absence of prescription medication coverage is associated with a reduced 
adherence to diabetes and hypertension oral medications. Providing medication coverage may 
help in increasing the probability for adherence. As such, there is a need for further studies to 
quantify the effect of recent changes of provincial insurance coverage. 
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The impact of medication cost coverage on optimal adherence to Hypertension and 
Diabetes Mellitus oral medications 
1.1. Chapter 1: Introduction The epidemiology and cost of Hypertension and Diabetes 
Hypertension (HTN) and Diabetes Mellitus (DM) are among the most widespread 
chronic diseases (CDs) in Canada; and they have profound effects on the Canadian population.1 
In general, CDs are noncontagious diseases with multiple risk factors.2 They are known to 
progress slowly and their symptoms arise after they have progressed. Thus, they are considered 
to have a long latency period; and they eventually cause functional impairment or disability.2 
CDs can also be referred to as chronic illnesses, non-communicable diseases, and degenerative 
diseases.1 HTN is defined as having an ambulatory blood pressure measurement of systolic 
and/or diastolic blood pressure equal to or above 135/85 mm Hg.3,4 DM, on the other hand, is 
defined as having a fasting blood glucose ≥ 7.0 mmol/L, 2-hour plasma glucose of ≥ 11.1 (using 
mmol/L (using in a 75 g oral glucose tolerance test), a glycated Hemoglobin ≥ 6.5% , or Random 
Plasma Glucose≥ 11.1 mmol/L.5 
In Canada, the current estimated prevalence of HT among adults aged 18 years and over 
is 17.3%, while that of DM is 7.1%.1 In 2011, it was estimated that 1 in 4 Canadians is either 
diabetic or pre-diabetic and the projection is that this will increase to 1 in 3 by 2020.6 By then, 
HTN and DM are projected to rise to 23% and 10.8% respectively.6,7 One in five Canadians with 
HTN also has DM.8 Financially, HTN and DM are placing a burden on the Canadian health care 
system with a significant cost on its economy. In 2010, the cost attributed to HTN was 
estimated to be $13.9 billion; whereas DM’s cost was estimated to be $11.7 billion.6,7 
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Extrapolation of these costs to the year 2020 is expected to result in a significant rise to $20.5 
billion for HTN and $16 billion for DM.6,7   
1.2. Management of Hypertension and Diabetes 
As with other CDs, HTN and DM do not occur from one cause, but originate from 
complex and multilevel risk factors over an extended period of time.9  Additionally, health care 
system related factors are important in the management and clinical outcome improvement of 
HTN and DM.10 These factors include the inadequate delivery of proper healthcare services by 
healthcare providers, either due to lack of knowledge and training, work-overload, or 
insufficient or absence of reimbursement by health insurance plans.9 These elements play an 
important role in the management and development of disease complications in patients with 
chronic diseases such as HTN or DM.11,12 
Upon diagnosis of HTN and DM, an optimal management plan is usually pursued in 
order to control and prevent adverse health outcomes from progression. Norris et al. propose a 
definition for chronic disease management based on a systematic review and Wagner’s model 
for chronic disease management.13,14 This definition entails centralizing the patient in 
healthcare delivery and providing healthcare through an organised, proactive, and multi-
component approach.  In this regard, evidence-based medications are the cornerstone of HTN 
and DM management.3,5 These include oral medications that can not only slow the progression 
of HTN and DM, but also reduce clinical adverse outcomes. In spite of the availability of such 
medications, several impediments still prevent the achievement of optimal results from the 
organized management plan.15,16 As a result, it is estimated-for example in HTN-that less than 
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25% of patients achieve optimal outcomes.17 Sub-optimal adherence is considered to be the 
main cause for non-ideal HTN and DM management.5,17   
1.3. Medication adherence 
In 2003, the World Health Organization (WHO) defined adherence to be: “the extent to 
which a person’s behavior – taking medication, following a diet, and/or executing lifestyle 
changes, corresponds with agreed recommendations from a health care provider”.9 Other 
terms that are closely related to adherence are: compliance, concordance, persistence, and 
obedience.  Although compliance and adherence were interchangeably used in the past, 
adherence is currently preferred because it suggests the involvement of patients in the 
decision-making process of their chronic disease management plan.18,19 This involvement does 
not necessarily mean that the patient will be choosing their therapy regimen. Rather, it signifies 
the patient as an important key for the success of their therapy plan by understanding the 
importance of treatment and contributing to the decision-making process.  
In reality, involvement of patients with their management plan can improve adherence 
to their medication regimen as prescribed.20-22 On the other hand, a lack of involvement may 
create doubts among patients that can impact following their regimen as prescribed. Thus, 
unlike compliance, the term “adherence” recognizes the importance of patients’ involvement in 
their prescribed medication regimen.16,23 In fact, optimizing pharmacological therapy before 
considering  patient’s medication adherence is inaccurate and can be costly.24  
Adherence to medications in CDs has been found to be associated with improved clinical 
outcomes.25 In a meta-analysis that looked back at three decades of research, sixty-three 
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related studies were assessed for the existence and magnitude of the correlation between 
adherence and clinical outcomes.25  In total, most studies (51 out of 63) had found optimal 
adherence to be related to positive outcomes, whereas 8 showed no effects on outcome, and 4 
had negative outcomes. Overall, adherent patients were at a 26% increase in the likelihood of 
experiencing positive outcomes in comparison to their non-adherent counterparts.25 However, 
some researchers have argued that adherence could not be significantly proven to mediate 
positive clinical outcomes.26,27 For example, in a prospective cohort study, 319 elderly patients 
(≥ 65 years old) were recruited, had their medication adherence assessed (using the Morisky et 
al.’s 4 question self-report scale), and were followed-up starting one year from their time of 
assessment.26  Although 123 participants were classified as non-adherent, statistically 
significant differences were not found between the adherent and the non-adherent patients for 
risk of selected adverse clinical outcome of hospitalisation, including emergency department 
visits, or death.28 Similarly, a systematic review looking at studies published from 1985 to 2003, 
investigated whether a relationship between adherence and blood pressure control existed.27 
Studies were included if they had used electronic records as their data source. The study 
concluded that there was no significant relationship between adherence and blood pressure 
control.27 The findings of this study and similar studies may be due to a small sample size, 
variation between definitions of adherence, absence of a cut-off point between adherence and 
non-adherence, and inconsistencies in measuring adherence.26,27,29 In fact, the choice for valid 
and suitable measurement of adherence is critical in order to evaluate the impact of adherence 
on clinical outcomes.18  
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1.4. Methods of assessing adherence 
It is necessary to have an accurate measurement method to assess adherence in order 
for treatment planning to occur effectively. Robust assessment is also necessary to examine the 
impact of treatment plan on health outcomes accurately. Hence, if outcomes are suboptimal, 
no alterations are made in the management plan until adherence has been validated by a 
reliable adherence measurement method.9  
The literature provides a wide range of options concerning adherence assessment, but a  
“gold standard” for the measurement of adherence in patients does not exist.18 Adherence 
assessment methods are  categorized by the WHO as objective and subjective methods.9,20,30 
Objective adherence measures include pill counts, pharmacy dispensing records databases, and 
electronic Medication Event Monitoring System (MEMS) devices.31-33 Other more intrusive 
methods in assessing adherence behaviour are biochemical tests and blood level monitoring of 
the medication of interest.34 Subjective measures include: patient-kept diaries,18 physician 
reports,32 report by others such as health care providers or family members,18 standardized 
patient administered questionnaires (such as Morisky’s structured questionnaire),28 and patient 
directed surveys (self-reporting)35,36such as the Canadian Community Health Survey that is 
carried out every year by Statistics Canada.37 Surveys are well known for their relative 
simplicity, effectiveness, and practicality, especially when assessment is needed to be carried 
out on a population level.35,36   
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1.5. Precision and practicality of different adherence measures in population-based 
epidemiological studies 
The effectiveness of self-reported surveys in estimating CD prevalence has been 
validated by previous research. For example, a study from Brazil, which included 907 
participants, interviewed patients and then measured their blood pressure. The specificity and 
sensitivity of self-reported HTN were 86.4% (95% CI: 84.3-88.6%) and 72.1% (95% CI: 69.3-
75.0%), respectively. HTN prevalence was estimated in this study to be 27.2% (95% CI: 24.4-
30.1%), which was similar to the accepted prevalence of this CD at the time (23.3%; 95% CI: 
20.7-26.1%).38 In terms of medication use, self-reported surveys also showed clear 
effectiveness. For example, in one study, which was carried out on 223 women (50 years and 
above), from the Women's Health Initiative Study, the researchers compared the agreement 
between length of medication use in self-reported surveys with that of pharmacy records. The 
sensitivity and specificity for the medication assessed was greater than 95%.39 Similarly, using 
the self-report surveys method, a study assessed the validity of medication use among 170 
patients with type II diabetes and assessed blood sample levels of Glycated 
hemoglobin (HbA1c).40  The study also validated self-reported adherence in a subsample by 
using MEMS- measured adherence as a comparison. Self-reported adherence had significant 
association with optimal levels of HbA1c.40 Also, within the subsample of 88 participants, self-
reported adherence was found significantly associated with the MEMS-measured adherence. 
Self-report measures, when compared as a measurement tool for adherence to pill-counts, had 
better correlation with serum levels. Fletcher et al. tested and compared the correlation of 
digoxin serum levels in patients with a cardiovascular disease, with pill counts and self-reported 
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interviews.41During the interview, patients were provided with a range of adherence levels 
(percentages) on visible cards and were asked to quantify their adherence. Meanwhile, in a 
different room, patients’ pills were counted. Following the interview, blood samples were taken 
to assess serum levels of digoxin. The participant’s responses received during the interview 
correlated with digoxin serum levels more than the pill count method.41  
Self-reporting through patients’ surveys  are the most practical and sound approach in 
assessing medication adherence determinants - especially for patient populations with chronic 
diseases including HTN and DM.42,43 The self-reporting method is evidently simple and valid 
compared with other measures.35,36 Although self-report subjective methods have been found 
to overestimate adherence more than objective measures. This overestimation may have been 
due to patient recall bias and social desirability and studies’ characteristics can impact  this 
phenomenon .31,44-47  For example, in a systematic review of predictors of adherence, 
overestimation of self-report measures was evident if studies had smaller sample size.31 
However, when all studies were combined, self-reports measures had lower adherence 
estimates.31 Variability among self-reported studies is most likely due to the low power of some 
studies. Accordingly, self-reports tend to be robust in large populations.31 
The pill count measurement method is simply carried out by counting the present 
number of dosage units (pills, capsules, tablets, puffs, etc.) returned by patient on the date of 
follow up. The dosage units are compared with the initial number of units that were provided 
and were expected to have been consumed by the specified scheduled date of follow up.18 The 
percentage of adherence is calculated by subtracting those two numbers (number present on 
the day of follow up from number initially provided) and dividing by the number of units that 
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should have been consumed. Multiplying the result obtained by a 100 gives us the adherence 
percentage. Pill counting can vary in accuracy in estimating the percentage of medication 
adherence. In fact, studies have shown that the pill count method tends to overestimate 
adherence levels.33,48 One example can be shown for this when patients discard their 
medication rather than consume it.49 Pill count, through comparing the number of pills with the 
original number dispensed, cannot convey the reasons behind non-adherence.18 Furthermore, 
counting can impose a sense of lack of trust in the patient that can further harm the 
relationship with health care professionals.  Most importantly, this method is not practical in 
population-based studies due to the reasons discussed above.50 For these reasons, pill counts 
should not be chosen as an optimal measure of adherence, especially on a wide level involving 
many participants.51,52   
Prescription refill records are centralized database systems that record patients’ 
medication prescription dispensing.46  Assessing adherence by these records relies on an 
assumption that upon dispensing the medications, patients are solely relying on one system for 
receiving and taking their medication.18 However, this method cannot verify if the patient did in 
fact consume the medication; and it also ignores the possibility that a patient may be receiving 
his/her medication elsewhere - such as from free samples from their health practitioner.46 
Finally and most notably, on a population level, electronic databases cannot provide the wealth 
of information that self-reports can, especially when financial, insurance, and or socioeconomic 
status are needed to be measured and accounted for.32  
MEMS are devices comprising of programmed unit bottles that record the time and day 
when the medication container is opened, a pill is removed from a blister pack, or an inhalation 
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device is actuated.18,33 MEMS cannot, however, monitor if the patient in fact ingested the 
medication. This leads to overestimating adherence, which occurs when patients open their 
monitored bottle without ingesting any pill.53 Alternatively, adherence may be underestimated 
in the MEMS method. This can occur in “pocket-dosing”, which is the act of removing more 
than one dose, ingesting one dose and placing the rest in their pocket to be taken later.53,54 
Above all, MEMS are inconvenient, expensive and cannot be practically representative in the 
real-world of adherence in the population.18  
Biochemical tests and blood level monitoring sometimes use nontoxic biological 
markers combined to the medication and can measure patients’ blood or urine medication 
levels. These levels can indicate adherence of patient to the particular medication.34 In some 
simplistic scenario cases, biochemical test monitoring serves in screening patients for 
adherence.55 Not all medications can be assessed following this method since some factors may 
affect blood levels besides adherence, such as diet and drug-drug interactions.46 Furthermore, 
serum medication levels can reflect only short-term adherence, hence patients who are aware 
of their monitoring may take their medication specifically for the test.56  Additionally, this 
objective measuring method has limited feasibility because it is expensive, invasive and 
impractical in large population studies.19  
1.6. Current adherence levels among populations with chronic diseases  
One quantitative review of 50 years of research looking at studies from 1948 to 1998 
concluded that the average rate of non-adherence to chronic disease medications is currently 
at 25%.31  Other studies report that, depending on patients’ conditions and how complex their 
treatment regimens were, 40% of patients or fewer generally do not take their medications as 
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prescribed.20 The World Health Organization (WHO) also reported that, in developed countries, 
on average, 50% of those with CDs are non-adherent to their medications.9,57,58   
Studies that have specifically measured HTN’s or DM’s medication non-adherence levels 
were alarming. A retrospective cohort study in the US included 21,723 participants who had 
started a single anti-hypertensive prescription-medication for their first time.59 Participants 
were considered adherent if they had dispensed their medication up to three months after 
their one-year prescription anniversary of the medication. The non-adherence percentage rate 
was 36% for angiotensin-II receptors antagonist (ARBs), 42%for angiotensin converting enzyme 
inhibitors (ACEIs), 50% for calcium channel blockers (CCBs), 57% for beta-blockers, and 62% for 
thiazide diuretics.  
Non-adherence levels tend to increase over time. A Canadian retrospective cohort study 
recruited 1220 subjects that had experienced their first cardiovascular event and then received 
statins for the first time. After one year of follow up, the linked prescription databases revealed 
that 39.7% of the study participants had stopped refilling their statin medication.60 This 
percentage increased to 71.8% by the 5th year of follow up.  
Similarly, primary non-adherence (also known as never taking the medication 
prescribed) is suboptimal in Canada.61 In a recent study in Quebec, patients - selected from 
linked electronic medical databases - were chosen if they have recently been prescribed a drug 
that they have never received before. Patients were considered non-adherent if they received a 
prescription and did not have it dispensed within a 9-month period.62 Almost one-third (31.3%) 
of 37,506 prescriptions were never filled by the 15,961 participants. Of the patients’ prescribed 
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anti-diabetic or anti-hypertensive medication, 29% (972 patients) and 42.3% (2,246 patients) 
never filled their medication prescriptions respectively.  
1.7. Importance and impact of non-adherence 
Medications are the cornerstone of effective chronic disease management plans. Thus, 
it is important for patients to adhere to their medications to prevent further complications of 
their disease.63 Adherence indirectly saves further avoidable costs. These costs can be related 
to occurrence or the acceleration of onset of complications, increasing risks of hospitalization 
and healthcare costs.63,64 Non-adherent patients face adverse events and poor health outcomes 
that are avoided by adherent patients.19 For example, non-adherence to anti-hypertensive 
medications can increase the risk of stroke by two folds.65  Similarly, non-adherence to anti-
diabetic medications can significantly increase the risk of cardiovascular and cerebrovascular 
complications.63,66  
1.8. Determinants of non-adherence/ adherence barriers 
When identifying adherence barriers, studies have shown that these barriers are 
interlinked. Accordingly, the reasons behind non-adherence are considered to be 
multifactorial.31,67 In the 2003 report on adherence for chronic diseases, the WHO illustrated 
adherence as a multi-dimensional factorial model.9 This model comprised of the five following 
constructs: 1) social and economic factors (which includes: poverty,  low level of education, 
unemployment, and culture and lay beliefs about treatment and illness); 2) health-care team 
and system-related factors (which includes: poor health services, absence or poor financial 
support by health insurance plans, short duration of consultations, limited ability of the system 
to educate patients and offer follow-up, and absence of knowledge about adherence and of 
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effective interventions for enhancing it); 3) condition-related factors  (which includes: 
symptoms, severity, progression of disease, and availability of effective treatment); 4) therapy-
related factors (which includes: accessibility of the drug, side effects, drug regimen, frequent 
changes,  treatment duration, and previous treatment failures); and 5) patient-related factors 
(which includes:  forgetfulness to take medication, knowledge, beliefs, perception, and low self-
efficacy).9 Although the WHO model aims to include all possible determinants for non-
adherence, it must be noted that some factors affect adherence in multiple ways. For instance, 
accessibility of medication can be assessed by the availability of the drug in a certain residential 
area; and it can also be assessed by whether the patient is able to afford purchasing that drug.  
Financial support systems, such as prescription medication cost coverage (PMCC), are 
important enablers that insure patients can afford purchasing the drug of interest. 
1.9. Medication cost and non-adherence 
Medication cost is one of the barriers that prevents medication adherence.68-70 This has 
been shown repeatedly in the literature. For example, in one study, high medication cost was 
selected by 17% of the study population as the most common reason for non-adherence.71 
PMCC can help those who are non-adherent because of the high medication cost and can assist 
in overcoming the cost barrier. In a population of patients that had Medicare benefits (a US 
national social insurance program), 55.5% of patients did not fill at least one prescription 
medication because they “thought it would cost too much” and 20.2% of patients chose not to 
fill a prescription because the “medicine [was] not covered by insurance”.72 Notably, 
cardiovascular medications accounted for 18%, while endocrine/metabolic agents represented 
7% of unfilled prescription medications in this study.72 These studies suggest that relieving 
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chronic disease patients from their high medication cost can help prevent non-adherence and 
overcome the high medication cost barrier.  
Canada’s drug-related health problems due to non-adherence constitute around an 
average of 35% of medication spending.73 This spending accounts for 140,000 hospital 
admissions and 35,000 deaths that occur every year due to non-adherence.74 Moreover, with 
the increase of drug costs (at an annual rate of 9%), the estimated cost of non-adherence-which 
is following suit - is estimated to grow to a staggering $14 billion in Canada.73-75  
1.10. Drug insurance coverage in Canada  
Canada is the only developed country that has a universal health insurance system, yet 
it does not offer universal coverage for medications.76 The Canada Health Act requires 
provinces to cover hospital, physician, and most medical laboratory testing services.77 This 
universal coverage does not include prescription medication use outside of hospitals. PMCC is 
certainly a patchwork of federal and provincial effort to include populations viewed as most in 
need for PMCC.78,79  The federal government covers the cost of prescription drugs for 
approximately 2% of the Canadian population including some Aboriginal populations, armed 
forces, Royal Canadian Mounted Police, veterans, and federal penitentiaries inmates.80 
Provinces therefore have developed different public PMCC plans for some groups of the 
population such as senior citizens, persons with low income and patients who face prescription 
medication costs that exceed a set percentage (for example 4%) of their household income. The 
latter discussed type of coverage is also known as catastrophic drug coverage.81 Most Canadian 
employers, on the other hand, do offer various levels of private PMCC plans for medication 
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coverage for their employees.80 Lastly, Canadians may opt to purchase their own private PMCC 
plan. 
   Because of medication coverage gaps within the Canadian population, it comes as no 
surprise that a significant number of Canadians do not have the needed support for cost 
coverage of their prescription medication.82-84 It is estimated that about 66% of Canadian 
households address out-of-pocket expenses for their prescription medication.37 In fact, when a 
cross-sectional study approach was used to determine the national proportion of cost-related 
non-adherence in Canada, about 1 in 10 people were found to have reported that their non-
adherence was cost-related.37 A similar study looked at only one chronic disease (HTN) in one 
year.85 However, because answers to “cost” as reasons for not taking medication were too few, 
reliable estimates could not be produced.  
Cost can be a barrier even with the availability of PMCC. In Quebec, thanks to provincial 
legislation, all residents are obligated to have PMCC.86 The provincial insurance agency (Régie 
de l’Assurance Maladie du Québec or RAMQ) provides drug insurance to approximately 50% of 
Québec residents which includes seniors, social assistance recipients, and those without private 
PMCC plans.86 The other 50% of residents have private PMCC insurance plans either because of 
their employment or they purchased PMCC independently. PMCC plans can either fully or 
partially cover drug costs. When partially covered, the patient pays part of the cost in the form 
of copayments. Though all residents have some kind of PMCC, a study showed that high 
medication copayment was still significantly associated with non-adherence.62 Compared with 
those who do not pay for their prescription medication, there was a 37% increase in the odds of 
non-adherence among patients who had the maximum copayment.62 As significant and useful 
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as these results were, they could not convey the actual prevalence and impact of the absence 
of PMCC for patients across Canada. Provincial law in Quebec is very different from the rest of 
the provinces in Canada and results could not be generalized across the population.  
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Chapter 2: The Literature Gap and Study Objectives 
I found quite a number of published studies on PMCC-related non-adherence to 
medications.64 Nevertheless, the obvious limitation observed was that most studies had looked 
at insurance coverage outside Canada. Even for studies carried out in Canada, researchers 
either focused on one province, or a particular year in time, or were not able to address 
insurance as a factor for non-adherence due to study limitations.37,85,87-89  I was not able to find 
a recent study that had measured the time-trend and impact of PMCC on optimal adherence 
specifically to HTN and DM medications. Among all chronic diseases, HTN and DM are causing 
the most significant preventable cardiovascular outcomes in Canada; and optimizing the care 
for patients with those two disease states is a dire obligation for the whole nation. Accordingly, 
there is a need to address the trend of the PMCC impact on non-adherence in a representative 
sample of the general Canadian population who has HTN and DM. Thus, my research objective 
is to measure the time-trend and impact of the association between absence of PMCC and 
medication non-adherence in people with HTN and/or DM. It is carried out through a repeated 
cross-sectional study design.   
The Canadian Pharmacists Association has called government and policy makers to 
assess evidence for gaining a clear understanding as to the reasons of financial barriers to 
optimal health outcomes.90 Measuring the magnitude of association between PMCC and non-
adherence will help us understand whether lacking insurance is causing a significant impact on 
Canadians and their medication adherence behaviour. Shedding light on this association in this 
way will quantify the burden of absence of PMCC on non-adherence to medications for HTN 
and DM. The study results can help policy makers and administrators in assessing the need for 
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action towards improvement of medication adherence. The results also distinguish the 
characteristics within the population most likely to be at a disadvantage from the lack of 
PMCC.91  
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Chapter 3: Methodology 
3.1 Study Design 
Repeated cross-sectional study design 
3.2 Study aim / objective 
To measure the trend and determinants of the association between absence of prescription 
medication cost coverage (PMCC) and non-adherence to oral HTN and DM medications among 
adults in Canada. 
3.3 Hypothesis  
The percentage of Canadians with PMCC has decreased over the study period and it is 
associated with a significant increase of non-adherence to oral HTN and DM medications. 
3.4 Data Source  
The Canadian Community Health Survey (CCHS) cycles 2007-2008, 2013, 2014 is the 
data source for this study.92 CCHS is a cross-sectional survey of a representative sample of 12 
years of age and older in all Canadian provinces and territories. The survey excludes 
populations living on reserves and other Aboriginal settlements in the provinces, full-time 
members of the Canadian Armed Forces, people that are placed in institutions, and persons 
living in the Inuit and Cree regions of Quebec (namely, Québec health regions of Région du 
Nunavik and Région des Terres-Cries-de-la-Baie-James).92 Altogether, these excluded 
populations account for about less than 3% of the representative Canadian population. This 
survey targets the Canadian population at a sub-provincial level (by health region or combined 
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health regions) and collects information related to health statuses, determinants, and health 
care utilization. The CCHS collects data on an ongoing basis where one year corresponds to one 
cycle - and targets the Canadian population as a whole. The survey is collected each year during 
the months of January to December and can be referred to as a “cycle”. Across two cycles, the 
collection is divided into 12 two-month collection periods. This facilitates the option of 
combining cycles. The CCHS collection years are combinable to facilitate examining the time 
trend.92 Samples drawn constitute a representative number of households in the population.  
 Since the year 2007, the survey has been carried out annually instead of once every two 
years. Every year, a simple random sample of around 65,000 participants is selected across all 
Canadian provinces and territories. The sample collected comes from three different sample 
frames: 58.5% of the sample is selected from a frame of the list of telephone numbers, 40.5% is 
from an area frame, and 1% is from the Random Digit Dialling sampling frame. These 
respondents provide reliable estimates to the 110 health regions. The multi-stage sample 
allocation strategy carried out by CCHS treats relatively all health regions and provinces with 
equal importance.  
There are three question content types in the CCHS questionnaire: core, optional and 
rapid response contents.93 Core content questions target all provinces during every collection 
period. Optional content includes questions that are selectively chosen by some provinces to be 
provided to their residents that are included in the survey.  Rapid response content questions 
are asked during a single collection period (which is two months) to the targeted study 
population as a whole across Canada.  
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3.5 Validity of CCHS 
Multiple steps are taken to perform data validation in CCHS.92 First, the CCHS team uses a 
validation program that compares estimates of the common content health indicators with that 
of the previous year. These estimates are taken at various geographic levels, in addition to 
using age and sex as estimates of comparison. Surveys which collect CCHS variables, other than 
Statistics Canada, are compared with CCHS results. The CCHS team searches for important 
differences between the surveys. This is done to check if there are any anomalies in the data. If 
the differences are significant, CCHS team investigates and documents the possible causes. 
Second, CCHS analysts look at many variables in-depth and publish analytical articles on specific 
themes carried out in the survey. In doing this, the analysts effectively identify errors in which 
variables may be holding. This practice increases the possibility of error detection and adds to 
the validation of the CCHS. Lastly, as an external validation measure, prior to release of the 
collected data, shared files are sent for a two-week review period to provincial and federal 
partners. These partners examine, scrutinize, and advise Statistics Canada on any concerns or 
abnormalities related to data quality. 
The validity of CCHS survey answers related to oral DM and HTN prescription medications 
has been studied by cross-examining the self-response of participants with prescription claim 
databases.94 Using Cohen's kappa coefficient as measure of agreement, answers for oral 
diabetic medication were found to have good to very good agreement [Kappa was found to be 
0.79 in 2001; (95%CI 0.76-0.82) and 0.87 in 2005 (95%CI 0.85-0.89)] and that responses related 
to hypertension medication had a moderate agreement [Kappa was found to be 0.46 in 2001; 
(95%CI 0.43-0.48) and 0.55 in 2005 (95%CI 0.53-0.57)].94 Other studies, mentioned previously 
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here, have supported the finding that self-reported adherence is a valid measure to use in 
surveys.38-40 
3.6 Weighting in CCHS surveys 
The weighting technique in CCHS ensures generalizability on a level from which the 
samples have originated. In other words, if a study sample with specific characteristics came 
from a province such as Ontario, then the inferences made from this study sample are 
generalizable and representative of people with similar characteristics in Ontario. The 
technique followed in weighting is a multi-step complex technique.95 Sarafin et al. has reviewed 
this technique explicitly.96 Households are selected according to the national prevalence of 
family size and age. For example, the prevalence of households with at least one “child” is 20% 
and therefore CCHS targets 20% of the households that have at least one child. To achieve this 
target, 7 steps are performed:  1. Removal of out-of-scope units that cannot be practically 
reached such as a demolished building or an institution, 2. Calculating household-level 
nonresponse weights within targeted population and redistributing those weights within the 
remaining population, 3. Combining the weights from the telephone and area sample frames 
and integrating them to avoid bias that might occur (this step is performed to avoid under-
coverage of the telephone sample frame), 4. Adjusting the household-level weights are 
adjusted using the inverse person-level selection probabilities for calculating person-level 
weights based on household size and age of household members,95 5. The interview process 
occurs in two steps. First, the interviewer contacts the household to complete the list of 
household’s members. Then, one person is selected for the interview and is contacted. If the 
person selected refuses to be interviewed, person-level nonresponse adjustment is carried out. 
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This is when the fifth step for adjusting person-level weight comes in. Person-level nonresponse 
is treated the same way as household-level nonresponse in step number two, 6. Reducing 
variance of the estimates by ‘Winsorization’.97 Because weighting is carried out through 
multiple steps, some units end up with extreme weights.  While potentially introducing a small 
bias, Winsorization reduces the variance estimates as a correction measure by applying lower 
weight values to outliers, and 7. Calibration to confirm the final weights’ total, indicating the 
population estimates that were initially defined at the household response level. The resulted 
weights of these steps are used to produce a representative sample of males and females 
within the age groups of the population. Variances in CCHS estimates are calculated using the 
bootstrapping method.98  Bootstrapping is: “a technique for estimating the variance and bias of 
an estimated parameter by repeatedly drawing random samples with replacement from the 
observations at hand, with the resamples having the same size as the original sample”. 99 For 
higher accuracy in this study, results were produced using bootstrap weights. Please see the 
CCHS user guides for further information on the weighting strategy.92,93,100-102   
3.7 Rationale for choice of survey 
In comparison to other available surveys that are similarly health-oriented, the CCHS is 
unique because it has a specific set of questions that are of interest for my study. Additionally, 
CCHS is carried out annually. To the best of my knowledge, of all the surveys available at the 
Research Data Centre (RDC) at the University of Waterloo, only the Joint Canada/United States 
Survey of Health103 contains very similar questions that are of interest.104 However, this 
particular survey was only carried out once in 2004 and was a joint study with the US targeting 
a smaller number of Canadian participants in the sample.  
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3.8 Cycle year selection   
The sample was drawn from 260,269 respondents that were included in cycles 2007-2008, 
2013, and 2014.The availability of the medication cost coverage question (which was an 
optional content question) was the main reason for choosing each cycle year. Therefore, to 
facilitate comparison across the years, provinces had to include the optional content PMCC 
question in their survey across at least two years. Ontario and New Brunswick were chosen 
because these provinces included the PMCC question and over several cycle years. 
3.9 Study participants   
Respondents were included in this study if they were 18 years of age or older on the 
date of the survey, had DM type II (DM II), or HTN, and have answered the questions about oral 
medication use and PMCC status. Excluded participants were either those who were pregnant 
upon diagnosis with HTN or DM II, had Alzheimer’s disease, had incomplete data about having 
HTN or having DM II or the status of their prescription medication cost coverage.100,105 
3.10  Exposure assessment: 
Exposure is the status of not having any kind of PMCC that paid all or part of the cost of 
respondents’ medications. This was assessed using the question: “Do you have insurance that 
covers all or part of the cost of your prescription medications?” 
3.11  Outcome assessment: 
The outcome is adherence to HTN and DM II medications. Adherence to medication was 
assessed using the following question for HTN “In the past month, have you taken any medicine 
for your high blood pressure?” for respondents who have HTN only. Respondents who 
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answered “No” to this question were considered to be non-adherent.   The question for DM 
was “In the past month, did you take pills to control your blood sugar?”, asked to respondents 
who have DM only. Respondents who answered “No” to this question were considered to be 
non-adherent.  For respondents who had both HTN and DM, answering at least one of the two 
questions with “no” was considered as non-adherence. To examine the robustness of this 
consideration among respondents with HTN and DM, I performed a sensitivity analysis by 
requiring the answer to both questions with “no” to consider the respondent as non-adherent. 
3.12 Confounders and Effect modifiers 
Factors that were considered as confounding variables were chosen based on the 
discussed WHO’s theoretical framework that conceptualized five main adherence domains.9 
Twenty-four variables available in the CCHS survey were examined for inclusion in the model as 
confounders. Error! Not a valid bookmark self-reference. shows the definition of each variable 
and the corresponding CCHS coding considered for addition in the model. 
These variables were available for all participants regardless which year the respondent 
participated in and regardless of the respondent’s background. Therefore, questions that were 
not applicable to be asked to some respondents were not included as confounders in the model 
as they were not available for all participants.  
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Table 1 CCHS variables that were considered in building the final model. 
Definition Variable Code 
Social and economic factors 
Derived variable for education level EDUDR04 
General health perception GEN_01 
Distribution of household income - National level (quintiles) INCDRCA 
Main source of Household income INC_2 
Health-care team and system-related factors 
Year _ 
Province GEO_PRV 
Having a regular doctor HCU_1AA 
Condition-related factors 
Cardiovascular Disease (stroke, heart disease) CCC_121, CCC_151, both 
Hypertension, DM, both CCC_073, CCC_101, both 
Therapy-related factors 
Asthma CCC_031 
Arthritis (arthritis, excluding fibromyalgia) CCC_051 
Back Problems CCC_061 
Migraine CCC_081 
Cancer CCC_031, CCC_031A 
Gastrointestinal: ulcer or have a bowel disorder such as Crohn’s 
Disease, ulcerative colitis, Irritable Bowel 
CCC_171, CCC_141 
Syndrome or bowel incontinence CCC_280, CCC_290 
Patient-related factors 
Age DHH_AGE 
SEX DHH_SEX 
Number of chronic diseases 
CCC_073 or CCC_101, or 
both 
Race SDC_ 
Smoking status: derived variable SMKDSTY 
Alcohol consumption: derived variable ALCDTTM 
Staying overnight in hospital, nursing home or convalescent 
home 
HCU_01 ( in 2007-2008)  
or  CHP_01 (in 2013-2014) 
Has taken flu shot  FLU_160 
 
 [26] 
 
Model building was done following the forward method. I performed the likelihood ratio 
test on each variable added to assess the model’s goodness of fit. Some variables, such as 
province, year, household income, were forced into the model to control for potential 
confounding imposed by geographical, time, and income factors. Other variables were excluded 
if they did not maximize the log-likelihood function of the full model compared to the current 
model. 
3.13  Statistical Analyses  
Data from included respondents were stratified according to PMCC status to 
respondents with or without PMCC. The descriptive statistics of the differences in 
characteristics of these two groups were assessed using Chi-square test of univariate analysis of 
significance on all bootstrapped weighted and unweighted variables of interest and t-test for 
continuous variables. Then, a bootstrapped weighted multivariate logistic model was 
constructed following the stepwise forward selection method approach. All variables of interest 
were categorical variables. The variables were constructed using the CCHS’s data dictionaries as 
well as the CCHS’s Annual Component of Derived Variable (DV) Specifications.93,100,101,106,107 I 
could not use the derived variable constructed by CCHS to identify DM type I and DM type II. 
This is because I was including cycle years before the time CCHS had constructed these derived 
variables. Instead, I followed the same algorithm CCHS had used to derive respondents with 
type I and type II.108 
To use total household income as a potential confounder, it was important to include a 
variable that accounted for change in time since the monetary value over time certainly would 
not have remained the same across the 7 years. Therefore, I used the imputed and derived 
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national level deciles variable which provides a relative measure of respondent’s household 
income to the household income of all other respondents, and is adjusted each year based on 
the consumer product index.100,109,110 The derived variable is produced in three steps. First, the 
low income cut-offs for each respondent’s family and community size is determined using the 
Survey of Labour and income.100 Second, individual ratios of reported or imputed household 
income to the low income cut-off -corresponding to respondent’s household and community 
size- are caluclated.100 Then, each respondent’s ratio is assigned a decile within the whole 
national data of ration.100 I collapsed each consecutive decile to form a quintile, in order to 
simplify statistical analyses and inferences. For example decile 1, which is the lowest 10% of 
household incomes, was combined with decile 2, the second 10%, to form the 1st 20% level of 
lowest household income amongst 4 other quintiles. 
The year of survey variable consisted of 2007 to 2008 (combined), 2013, and 2014. 
While New Brunswick included the PMCC question in all years, Ontario only included the PMCC 
question starting 2008. Therefore, since 2007 only included respondents from New Brunswick, I 
combined years 2007 and 2008 to have a sample size that is comparable to 2013 and 2014.  
It is common and feasible to combine CCHS cycles; and the risk of participants’ re-
inclusion is low.111  To protect participants’ confidentiality, identifying respondents across the 
years to remove any possible re-inclusion of an individual is not allowed. However, CCHS does 
not include respondents more than once over a period of five years.95  Since I was including 
cycles that span over seven years, the CCHS focal point and CCHS subject matter experts from 
Statistics Canada addressed my concern of possible re-inclusion, by responding that “The 
likelihood of an individual being a respondent in more than one cycle is very low” and that “The 
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CCHS does not have an estimate of the proportion of respondents in the annual files who have 
previously been a respondent to the CCHS annual component" and that “this proportion could 
be higher in rural low-density areas and lower in urban high-density areas”. This confirms that 
re-inclusion of individuals will not be a significant concern in this study.  
A P-value less than 0.05 was considered statistically significant in the analysis. Variables 
that were significant in the univariate analyses tests were retained in the final model if they 
were significant in the likelihood ratio test (using Wald’s t-test); and increased the fitness of the 
model as assessed by the Akaike information criterion. Year of survey, province of residence, 
and total household income, regardless of statistical significance, were forced into the model to 
account for geographical differences, policy differences in PMCC in the two provinces, as well as 
if any policy change had occurred over time.  
To test for potential effect modifiers, interaction terms were introduced in the model. 
Age, sex, income, and cancer (i.e. diagnosed with cancer or previously had cancer) variables 
were tested for effect modification.112,113  Additionally, testing for effect modification was also 
done by stratifying the study group by age, sex, income, and cancer and comparing the odds 
ratios (ORs) to the overall model. 
Multicollinearity, between variables included in the final model, was tested using 
Spearman’s rank correlation coefficient.114 This method, unlike the Variance inflation factor, 
can be used to measure collinearity between independent variables that are not only binary but 
also for multi-level ordinal variables. Spearman’s rank correlation coefficient, unlike Pearson’s r-
correlation, is able to measure collinearity when variables may not necessarily have a linear 
relationship but rather a non-parametric one. The cutoff I used was more than 0.7.115  
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SAS®, version 9.4 (SAS Institute Inc, Cary, NC) was used to perform the statistical 
analysis. Main model outputs of point estimates and ORs were compared using  STATA® version 
14. The results were exact to the hundredth decimal point in both statistical programs. 
3.14  Missingness in data 
Because the pattern of missingness was arbitrary, I followed the Fully Conditional 
Specification method (FCS) available in SAS®.116 The FCS method provides the possibility to 
factor in the complex sample selection design of strata and clusters. However, due to 
confidentiality reasons, analysts using the CCHS data are blinded from obtaining these strata 
and clusters of which the CCHS randomly selected the sample from. Instead, we are provided 
with bootstrap weights that are generated 500 times with replacement. To overcome this 
limitation, I was able to apply the bootstrap weights the CCHS has provided us with, instead of 
the strata and clusters needed for the FCS procedure. I confirmed the robustness of my method 
with a specialist from the Data Analysis Resource Centre at Statistics Canada who confirmed 
that my proposed procedure was reasonable provided that the imputation is capturing the 
variability due to imputation, which it did. 
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Chapter 4: Results  
4.1 Study sample: 
The steps of extracting the sample are illustrated in Figure 5 (unweighted) and Figure 6 
(weighted) that are available in Appendix A. The unweighted study population consisted of 
23,215 participants. The weighted bootstrapped total number of participants was equal to 
8,696,520.   
4.2 Descriptive statistics  
Table 12 and Table 13 (Appendix B) describe the characteristics among those with and 
without PMCC. Almost one third (31.2%) of participants were from years 2007-2008 while 
years, 2013 and 2014, consisted of 34.3% and 34.4% of the  total participant population 
respectively. Over half of the study population were female (51%), and 48% were 65 years of 
age or older. The full descriptive statistic results are provided in Table 12 and Table 13. Over the 
study period, the characteristics of respondents were similar. Figure 7 (Appendix B) illustrates 
the time-trend of respondents demographics. Figure 7 shows the trend of the percentage of 
people with both HT and DM over the study period.  The prevalence of DM and HTN and people 
with both HT and DM increased over time.   
Overall, 20% of the study population indicated that they did not have any drug 
insurance that covered all or part of the cost of their prescription medication. The majority 
without insurance were middle aged (45-64) and this percentage increased slightly over the 
study period by 0.8%. Mainly, 28% of Canadians were non-adherent to either DM or HTN oral 
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medication. Specifically, 34.6% of those who do not have insurance were non-adherent while 
22.6% of those who have insurance were non-adherent.  
4.3 Time trend 
Overtime, the proportion of the participants who do not have PMCC increased slightly. 
When comparing between years 2007-2008 and year 2013, the proportion of people without 
insurance did not change (19.6%). However, this percentage increased slightly by 5% (or 1% in 
absolute terms) to 20.7% in 2014 [Figure 1]. 
Figure 1: Weighted percentage of Canadians who do not have medication insurance from 
2007 to 2014 
 
Overall, the percentage of non-adherent patients decreased significantly by 8.9% (or 
2.6% in absolute terms) over the study period from 29.3% to 26.7% (Figure 2).   
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Figure 2 Weighted percentage of Canadians who are not adherent to oral medications of 
either diabetes or hypertension from 2007 to 2014 
 
While the percentage of non-adherence decreased across all groups (with or without 
PMCC) by 8.9%, those without insurance, showed less profound improvement in their 
adherence (8.3%) compared to those who had insurance (10.8%) (Figure 3). 
Figure 3: Weighted percentage of Canadians who are not adherent to oral medications of 
either diabetes or hypertension stratified by PMCC from 2007 to 2014  
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When expressing the association between PMCC and adherence in absolute risk 
reduction (ARR) term (the difference between the percentage of non-adherent cases of the 
PMCC group from the percentage of non-adherent cases of the control group), the impact of 
PMCC on adherence did not change over the study years and remained at 8% (Table 2). The 
relative risk reduction (RRR) (that is ARR divided by baseline adherence rate), also did not 
substantially change over the years. The number needed to treat (NNT) (i.e. the number 
needed to provide insurance to in order to avoid one case of non-adherence-assuming a 
causation relationship does exist) was 13 (Table 2). 
Table 2 Relative, absolute risk reduction and numbers needed to treat (with providing 
insurance) for each year. 
Year Absolute Risk Reduction  
(ARR) 
Relative Risk Reduction  
(RRR) 
Numbers Needed  to treat  
(NNT) 
2007-2008 8% 13% 13 
2013 8% 12% 13 
2014 8% 12% 13 
4.4 Model Building 
The final number of confounding variables included in the model was twelve and 
included:  Respondents’ socio-demographic characteristics (age, sex, household income, and 
respondent’s highest acquired level of education), condition and therapy related factors 
(diagnosed with cancer or having suffered previously from cancer, had a cardiovascular disease 
such as stroke or heart disease or had either HTN or DM or both, other CDs could not be used in 
the final model due to inconsistencies of data availability, statistical non-significance, or non-
improvement when testing for goodness of fit and because my observational study measured 
self-reported responses, respondents with dementia were excluded to avoid jeopardizing the 
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integrity of responses, as these responses depended on memory) patient-related factors 
(smoking status and flu shot usage), and health care resource use (had a regular medical 
doctor, the province of residence, and the year the survey was taken).37,117-119 Four variables 
were ordinal including: education attainment (less than secondary school, secondary school, 
and post-secondary), year of survey (2007-2008, 2013, and 2014), age (18-29, 30-44, 45-64, and 
65 and above), and household income (quintiles of income within the whole population).  The 
remaining nine variables were binary. Correlation between all variables of interest was well 
below 0.7.   
4.5 Multivariate logistic regression  
Participants who did not have insurance had an estimated crude odds ratio (OR) of 0.69 
for adherence to either DM or HTN oral medications, compared to those who did have 
insurance. After adjusting for possible confounding factors, the odds of adherence increased to 
0.77. The OR estimates along with corresponding 95% Confidence Intervals (95%CI) both from 
the crude and full model outputs are illustrated in Table 3. The full model output is illustrated in 
Table 14 in Appendix C.  
Table 3: Odds ratios of adherence among people without insurance vs. people with insurance 
in crude and full models 
Model Effect Odds Ratio 
Estimates 
95% Wald 
Confidence Limits 
Lower Upper 
Crude Model No Insurance vs. 
Insurance 
0.685 0.589 0.796 
Full Model 0.774 0.657 0.911 
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4.6 Testing for effect modification 
In comparison to the full model, the model fitness did not increase substantially when 
the interaction terms were introduced (table 4). The results of both effect-modification 
analyses (introducing interaction terms and performing stratified analysis) are displayed in 
Table 5. When the interaction between insurance and age, insurance and sex, insurance and 
cancer, and insurance and income were added, the OR remained around 0.7 (Table 5).  
Table 4 Model Fit Statistics 
Testing for Effect 
Modification 
Parameter Effect 
Intercept and 
Covariates 
Difference 
(interaction 
– Full 
model) 
Association of 
Predicted 
Probabilities and 
Observed 
Responses 
C-statistic 
-2 Log L 
Full model 
No Insurance vs. 
Insurance 
9086069   0.692 
In
te
ra
ct
io
n
 
Insurance * 
Age 
9084605 -1463.9 0.691 
Insurance *Sex 9086068 -0.7 0.691 
Insurance 
*Cancer 
9085539 -530 0.691 
Insurance * 
Income 
9083968.3 -2100.7 0.691 
 
When stratifying the analysis by age, absence of PMCC showed higher OR for adherence 
among older individuals (≥65) compared to younger individuals (<65) and people with no 
cancer compared to those who had a history of the disease. Stratification by sex or income, on 
the other hand, did not change significantly the association between PMCC and adherence 
[Table 5]. 
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Table 5  Results for testing variables age, sex, cancer and income as potential effect modifiers. 
Testing for Effect Modification 
Parameter 
Effect 
Odds 
Ratio 
Point 
Estimates 
95% Wald 
Confidence 
Limits 
Lower Upper 
Full model 
No 
Insurance 
vs. 
Insurance 
0.774 0.657 0.911 
 In
tr
o
d
u
ci
n
g 
in
te
ra
ct
io
n
 
te
rm
 
Insurance * Age 0.692 0.636 1.743 
Insurance *Sex 0.771 0.883 0.995 
Insurance *Cancer 0.683 0.790 1.105 
Insurance * Income 0.785 0.849 1.096 
St
ra
ti
fi
ed
 a
n
al
ys
is
 
By age 
≥65 0.870 0.705 1.073 
< 65 0.751 0.620 0.910 
By Sex 
Males 0.769 0.596 0.991 
Females 0.763 0.617 0.945 
By Cancer 
Cancer 0.661 0.402 1.085 
No Cancer 0.789 0.666 0.936 
Income 
Low 
Income 
0.739 0.541 1.01 
Middle 
and high 
income 
0.782 0.653 0.936 
 
4.7 Subgroup Analyses 
The subgroups analyses yielded ORs for adherence ranging from 0.7-0.8 as shown below 
in Figure 4.  This figure illustrates the ORs  (in orange dots) of adherence when PMCC is absent. 
Each orange dot represents the estimation point of the OR of each subgroup analysis carried 
out-along with corresponding 95%CI. The association between insurance and adherence did not 
change significantly when patients who shared the same province of residence, same age 
group, or both province and age were analyzed separately.   
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Figure 4: Odds Ratios of Adherence with No PMCC in Subgroups with 95% Confidence 
Intervals. 
 
Additionally, Figure 9 and Table 15 in Appendix D  illustrate the OR estimates of 
adherence when PMCC is not present in further subgroups tested. Interestingly, no PMCC 
among high-income patients in New Brunswick who are less than 65 years of age increased the 
odds for adherence by 12% (i.e. no PMCC had a protective effect) as compared to those who 
had PMCC-albeit this association was not significant (Table 15). Similarly, no PMCC showed a 
protective effect among patients who have been using insulin for 10 years or more, where the 
OR for non-adherence was 1.09 (95%CI 0.62 to 1.94) (Table 15). On the other hand, the OR of 
the association between PMCC and adherence in patients who have been using insulin along 
with their oral anti-diabetic for less than 10 years was 0.5, (95% CI 0.16 to 1.52). When I 
performed subgroup analyses depending on having DM only, HTN only, and both HTN and DM, 
the association between not having insurance and adherence was the most profound among 
0.4 0.5 0.6 0.7 0.8 0.9 1 1.1 1.2 1.3
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New Brunswick-above 65
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patients who had only HTN (OR=0.72, 95%CI 0.59 to 0.88 ) and was not significant among 
patients with DM only or with both HTN and DM (Table 6).   
Table 6 Subgroup analysis for DM only, HTN only, and DM&HTN together 
Number of 
participants 
Subgroup 
Parameter 
Effect 
Odds Ratio 
 
95% Wald 
Confidence Limits 
1735 DM only No 
Insurance 
vs. 
Insurance 
0.908 0.539 1.529 
17084 HTN only 0.721 0.592 0.878 
4396 HTN with DM  0.999 0.726 1.374 
 
Among Ontarians who were 65 years of age or older, the estimated OR of adherence 
with not having PMCC for this subgroup was 0.75 (95%CI 0.61 to 0.93). Remarkably, 17.1% 
(n=1819) of those patients answered “no” to having PMCC, in spite of having an automatic 
PMCC through the Ontario provincial plan.120 Those patients represent 6.2% of the total study 
population who were classified to having no PMCC. In Ontario, once a resident turns 65, they 
become automatically covered by the Ontario Drug Benefit plan.120 According to their income 
status, they may be exempted from paying the $100 annual deductible.120 Additionally, should 
their household circumstances meet the criteria and their income is below the specified 
amount, the co-payment for every prescription that they receive is reduced from $6.11 to 
$2.00.120 As for people from New Brunswick, I was not able to quantify the potential 
misclassification since New Brunswick's drug coverage plan is quite different from that of 
Ontario's. In New Brunswick, seniors that turn 65 years or are older have a 60 days notice which 
they receive through the mail that they have to apply for to obtain provincial coverage for 
prescription medication.121 This provincial coverage strictly depends upon income status. Those 
meeting the conditions, do not have a deductible but have a copayment of $9.05 for each 
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prescription, which is capped up to an annual of $500 of prescription co-payments.122 Those 
that do not meet the low-income criteria have the option to purchase a premium through the 
province.122 This type of premium is also strictly dependent upon their gross annual income and 
number of household members.122 The premiums and copayments increase with increasing 
gross income levels and is different for individuals and couples with or without children.122 I was 
not able to find previous literature that tried to estimate the number of patients who access 
provincial prescription plans in New Brunswick.  
A subgroup analysis was carried out for those who had PMCC (Table 7), depending on 
the type of insurance. The type of insurance did not impact significantly adherence to DM and 
HTN medications. The OR for those who had employer or private insurance versus 
governmental insurance was found to be 1.10 (95%CI 0.91 to 1.32). On the other hand, having 
more than one plan was associated with better adherence. Those who had more than one type 
of insurance had higher odds of adherence (OR=1.44, 95%CI 1.12 to 1.86) as compared with 
having only governmental insurance.  
Table 7:Odds Ratios of Adherence with Insurance type among insurance subgroup in 95% 
Confidence Intervals. 
Subgroups 
Odds Ratio 
Estimates 
95% Wald 
Confidence Limits 
Employer/Private vs. Governmental 
insurance 
1.095 0.908 1.319 
Mixed plans (more than 1 type) vs. 
Governmental insurance 
1.442 1.117 1.862 
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4.8 Sensitivity analyses 
Unlike the main analysis, where participants who had both HTN and DM had to have 
answered yes to both medications to be classified as adherent, I carried out sensitivity analyses 
with four different scenarios to consider participants as adherent to test the robustness of my 
definition of adherence (Models #2-5, Table 8). None of the sensitivity analysis caused a large 
change in the OR in all of the studied scenarios.123 
Table 8 Comparison of four different adherence definition scenarios to the main analysis, 
when patients have both HTN and DM 
Model # 
Criteria 
when having both HTN and DM 
Parameter 
Effect 
Odds 
Ratio 
Estimates 
95% Wald 
Confidence 
Limits 
1: Main 
analysis 
Adherent if response to both 
medications = yes 
No 
Insurance 
vs. 
Insurance 
0.774 0.657 0.911 
2 
Adherent if response to either 
medication = yes.  
0.739 0.618 0.883 
3 
Adherent if answered yes to at least 
one medication. It is allowed for the 
other medication’s answer to be: 
“don’t know/ missing”. 
0.773 0.656 0.911 
4 
Adherent if answered yes to at least 
one medication. It is allowed for the 
other disease’s answer to be: 
“no/don’t know/ missing”. 
0.738 0.616 0.883 
5 
Patient was considered non-
adherent, if the answer was 
confirmed to be “no” to adherence 
question. Patients were only 
considered to be non-adherent if 
responded no to the first disease 
and don’t have the other disease; or 
if they answered “no” to both. 
0.736 0.615 0.881 
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I carried out sensitivity analyses by changing the answer of Ontario seniors and all seniors, and 
the odds did not shift substantially. The results of this analysis are illustrated in Table 9. 
Table 9 Sensitivity Analyses for changing senior's response to having insurance 
Number of 
participant 
included 
Criteria 
Parameter 
Effect 
Odds Ratio 
Estimates 
95% Wald 
Confidence Limits 
23215 
Full model from main 
analysis  
No Insurance 
vs. Insurance 
0.774 0.657 0.911 
23215 
Assuming all senior 
Ontarians have insurance 0.744 0.609 0.908 
23215 
Assuming all seniors have 
insurance 0.743 0.604 0.914 
 
Misclassification of DM type I patients as type II was suspected when some diabetic 
participants were found to be using insulin early on in their lives, at a very young age, but also 
answered questions about adherence to their oral medication. I observed that all participants 
who have answered “yes” to having diabetes, were provided with the question for adhering to 
oral medication for diabetes, and the question was not restricted to those who had DM type II. 
Statistics Canada’s algorithm that aimed to differentiate DM type II from type I, classified 
respondents who have answered “yes” to adhering to oral anti-diabetic medications as being 
type II. Though, evidently, some type I individuals seemed to have answered “yes” to adhering 
to oral medications. Thus, this may have been the reason for some patients with DM type I to 
be included in the study. This misclassification was found to affect 1% (289) of the study 
population. I performed sensitivity analyses by removing those diagnosed with DM at an age 
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less than 30. Estimated ORs were very similar after the removal of those patients, when 
compared to the main analysis. Table 10 shows the odds before and after this removal.   
Table 10 Sensitivity analyses for removing suspicious DM type I participants 
Number of 
participant 
included 
Criteria 
Parameter 
Effect 
Odds 
Ratio 
Estimates 
95% Wald 
Confidence 
Limits 
23215 
Full model of the 
main analysis 
No 
Insurance 
vs. 
Insurance 
0.774 0.657 0.911 
22987 
After removing 
patients who were 
diagnosed with DM 
at age less than 30 
0.784 0.664 0.926 
1735 DM respondents only 0.908 0.539 1.529 
1641 
DM participants after 
removing those 
diagnosed at age less 
than 30 
0.914 0.537 1.558 
 
4.9 Handling Missingness in Data  
About 5% (1,153) of respondents had missingness in one or more covariate-other than 
the exposure and outcome. I managed missingness in the data by implementing three 
strategies. First, in the main analysis, since missingness in the data did not exceed 5%, I 
concluded that the size of missingness was small to a relatively large sample size, I followed the 
educated-guessing  approach as the form of imputation of any missing data.124 Hence, when a 
variable had a missing value, I assumed that the answer to this question was “no” (i.e. variable 
value=0). For example, for those who did not answer the smoking status question, the initial 
assumption was that they were non-smokers. When the variable was multileveled, I assumed 
that the missing value was the lowest value. For example, for missing education level, I 
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assumed the participant had the lowest level of education achievable. By not following the 
mean/modal imputation approach (that is choosing to replace missing values according to the 
modal category), I was able to avoid this recently un-preferred approach as it has gained a 
growing concern for its cause of reduction of data variablility.125 
Second, I managed missingness by removing participants with missing value in at least 
one variable. In this case, the OR produced did not differ substantially (0.77, 95%CI 0.60 to 0.99) 
as compared to the main analysis (0.77, 95%CI 0.66 to 0.91).  The results before and after the 
removal of missing values are displayed in Table 11. Third, I carried out 5 multiple imputations 
by fitting a logistic regression to predict the missing variable’s value by using all other covariates 
(Models #3 to 7,Table 11) following the assumption that missingness occurred at random. The 5 
different imputations in Table 11 produced very similar ORs to the main analysis (Model #1). 
Table 11: Missingness Diagnostics 
Model # Criteria 
Parameter 
Effect 
Odds 
Ratio 
Estimates 
95% Wald 
Confidence Limits 
1: Main analysis 
Initial Assumption for 
missingness to apply 
lowest level 
No 
Insurance 
vs. 
Insurance 
0.774 0.657 0.911 
2 
Removing missing data- 
(1212 observations  were 
removed) 
0.769 0.596 0.991 
3 Imputation Number=1 0.777 0.659 0.915 
4 Imputation Number=2 0.777 0.660 0.915 
5 Imputation Number=3 0.775 0.658 0.913 
6 Imputation Number=4 0.776 0.659 0.914 
7 Imputation Number=5 0.773 0.656 0.910 
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Chapter 5:  
5.1 Discussion 
Over the study period, the percentage of participants without PMCC in Canada 
increased slightly from 19.6% in 2007-2008 to 20.7% in 2014. Absence of PMCC is associated 
with 23% relative decrease in adherence to oral DM and HTN medications in comparison to 
those who had PMCC (OR 0.77, 95%CI 0.66 to 0.91). Correspondingly, the absence of PMCC is 
associated with an 8% absolute decrease in adherence to oral DM and HTN medications. This 
means that with assuming a causation relationship, providing PMCC to 13 patients, may help in 
preventing one case of non-adherence. In a subgroup analysis, for those who had PMCC, I 
found that having more than one type of insurance increases the odds of adherence. 
The percentage increase of 1% in the absence of PMCC represents a substantial number 
of Canadians without insurance. Numerically speaking, if we were to extrapolate these findings 
in 2016, a 1% increase would mean that around 360,000 additional Canadians are without 
PMCC. According to reports on National Health Expenditure Trends reported by the Canadian 
Institute for Health Information (CIHI), the percentage of out-of-pocket costs for drug 
expenditures increased from 33% in 2007 to 39.6% in 2012.126-128 Absence of PMCC in my study 
may explain some of the increase in out-of-pocket expenditure of medications in Canada 
observed in the CIHI study.  
PMCC in Canada is closely related to the economy.129 A study found that over the time-
period between 1997 and 2009, Canadians were facing increasing out-of-pocket expenses.129 
Additionally, the first and second lowest household income quintiles were found to have higher 
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out-of-pocket expenses in comparison to the remaining quintiles (that is third, fourth, and fifth 
household income quintiles). In my study, almost one half (47%) of the study population came 
from the first and second lowest household income quintiles; and hence absence of PMCC, that 
is more profound among this strata of the population, may explain the increase in non-
adherence over time. It can be speculated that the economic crises of 2008, which was 
associated with increased unemployment rates, has caused this increase in the absence of 
PMCC percentage. Additionally, with the changing economic landscape post-crisis, employer-
offered medication insurance may have been restricted to a lower number of employees, with 
a less-generous coverage, by comparison to the pre-2008 era.  
Previous research has shown that financial burden is a major obstacle that prevents 
patients from adhering to their medications.130 My study demonstrated that absence of PMCC 
is associated with a significant proportion of non-adherence to specifically two of the most 
devastating chronic diseases (i.e. DM and HT), even after controlling for all other patient, 
disease and health-care system characteristics. The results of my study provide the empirical 
evidence that offering PMCC to Canadians is essential to help more patients adhere to their 
medications. This would be far overarching important results for public health in Canada and 
would potentially lead to cost-saving for the Canadian health care system.76    
My study’s results also showed that having a cardiovascular disease (heart disease or 
stroke) is associated with higher odds of adherence, in comparison to those who do not have 
this comorbidity.131  This finding agrees with previous research which indicates that those who 
have comorbidities have a higher probability of adhering to their medication.132 Patients who 
suffer from multiple CDs usually see more health care professionals and have a higher 
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realization of the devastating consequences of their diseases.132 This may partly explain the 
results of my studies. On the other hand, respondents with a history of cancer or those with 
both HTN and DM showed lower odds for adherence. According to previous research, cancer 
survivors and hypertensive people with comorbidities show lower rates of adherence.133,134 It 
seems that different comorbidities are associated with adherence differently, where some may 
decrease the odds of adherence such as having a history of cancer, or having both DM and HT; 
while others increase the odds such as suffering from stroke or heart disease. This should raise 
concerns that some, but not all comorbidities, may reduce adherence.   
My results showed a significant improvement in adherence to DM and HTN medications. 
This is consistent with the significant improvement of medication adherence that was noted 
over time in the literature - both among new users and prevalent users.135 For example, a large 
study included 33,646 patients that were discharged post-myocardial infarction. Over the eight-
year study period (1995-2003), adherence rate increased from 38.6% in 1995 to 56.2% in 2003 
amongst those who were prescribed statins (p value <0.001).135 This improvement can be 
explained in two ways. First, we have an aging population in Canada; and studies have shown 
that older people are more adherent to medication than younger counterparts.119 In fact, in my 
model, increased age was associated with increased odds of adherence. Second, aside from 
aging, there is an increase in chronic disease burden in the Canadian population which is 
generally associated with the increase of adherence over time.136 My study has shown that 
people who had cardiovascular diseases (such as heart disease or stroke) were at higher odds 
for adhering to their medication. Thus, the increase in age and CD burden over time may then 
explain increased adherence.  
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Lack of PMCC may have deprived patients from taking full advantage of this 
phenomenon of improving adherence across patients groups. In my study, although there was a 
trend of improvement of adherence over time, the extent of improvement amongst those 
uninsured may have been hindered because of absence of insurance. Thus, those without 
insurance were at a lower advantage for adhering to their medication.137 This was confirmed 
when I carried out the subgroup analysis for those who had PMCC. Here, I found that having 
two types of insurance, as compared to one type, increased the odds for adherence. This 
confirms a dose-response or exposure-response relationship. That is, an increase in insurance 
coverage increases the odds for adherence. 
5.2 Advantages and strengths of Study  
A repeated cross-sectional study method for answering the question of interest is of 
advantage over other designs.138 First, the design provides a valuable glimpse of the real-world 
association between no PMCC and adherence in the Canadian population with DM II and HTN 
at multiple points in time. Second, this design also provides a clear examination of the time-
trend of the impact of lack of PMCC on medication adherence to two of the most important 
chronic diseases in Canada. And third, this study examines a relatively large sample that is 
representative of the Canadian population.   
5.3 Limitations  
In addition to the fundamental limitations of observational studies, several specific 
limitations can be noted in my study. First, a misclassification occurred when senior Ontarians 
denied having PMCC, in spite of the fact that, in Ontario, PMCC for seniors is automatic and 
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activated upon showing a valid health card to the pharmacy while picking up prescription 
medication after a patient’s 65th birthday. Due to the presence of a deductible in Ontario, a 
misunderstanding may have occurred, in which some study participants may have not 
considered this kind of insurance as PMCC.139 Because my results did not change when this 
group was removed, it seems that seniors with the wrong perception of not having insurance 
when they are clearly eligible are at the same risk of non-adherence. Thus, misperception about 
PMCC is comparable to not having PMCC and is associated with non-adherence.  A previous 
study published in Statistics Canada’s Health Report Catalogue, found that 49% of seniors in 
1996/1997 did not report acquiring PMCC when being surveyed, although they were eligible for 
provincial benefits.139 The study also found that provinces that did not impose deductibles were 
less likely to underreport their insurance status.139 In my study, this percentage was not 
substantial (6.8% of eligible Ontarians) and numerous subgroup analyses were carried out to 
quantify the odds of adherence in the absence of PMCC while controlling for age. A similar 
argument can be put forward for seniors in New Brunswick, regardless of the difference in 
coverage in that province. 
Another unavoidable misclassification may be the inclusion of participants with DM type 
I. A very small proportion of the study participants were found to have type I diabetes instead 
of type II because the algorithm that was developed by Statistics Canada, indiscriminately 
allowed participants that had answered “yes” to adhering to oral medication to remain in the 
study although they were diagnosed with DM early on in their lives (for example at 2 years old). 
The proportion of individuals that may be inadvertently included in my study in spite of having 
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DM type I, was found to be low and the sensitivity analyses illustrated that this misclassification 
did not change the results significantly.  
  Third, a misclassification may have occurred if participants answered incorrectly and 
overestimated their adherence to medication. Arguably, overestimating non-adherence is 
highly unlikely. The one month cut off is a very high threshold for not adhering to medication. 
Hence, flagging non-adherence is most likely an underestimation in this study. Since some 
patients may not have been using their medication for some time yet never reached one month 
for becoming considered as non-adherent. 
Fourth, respondents were considered to be receiving an antihypertensive medication if 
they self-reported having high blood pressure or having been diagnosed with high blood 
pressure by a medical doctor. There is a possibility that some patients may have had 
hypertension but were never prescribed an antihypertensive medication. Similarly, some 
patients may have been diagnosed with DM type II but were never put on antidiabetic 
medication. Due to the limitations of the data, the extent of this possibility could not have been 
sought out. A recent update about the epidemiology of hypertension in Canada found that 
about 90% of respondents who self-reported having high blood pressure also indicated that 
they were receiving treatment.140 Hence, it can be speculated that 10% of patients who were 
classified as non-adherent in fact were not prescribed medication for their condition. However, 
this misclassification could not affect patients with PMCC differently from patients without 
PMCC. The decision made by prescribers to prescribe is probably not affected by patient’s 
insurance status. Thus, even if this misclassification does exist, it is mostly non-differential, and 
hence could not have affected the estimated OR of the association between PMCC and 
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adherence to HTN and diabetes medications. On the other hand, even if this misclassification is 
differential, it would have resulted in underestimation of the true association between PMCC 
and adherence. In this case, patients who have insurance are more likely to receive a 
prescription, as they might visit with their physicians more frequently. This would mean that a 
larger percentage among patients with PMCC is misclassified as non-adherent when compared 
to patients without PMCC. This would have yielded an OR that is closer to the null hypothesis 
than the “true” OR. Hence, the original calculated odds in my study would be an 
underestimation to the actual odds if this misclassification is for example illustrated in fact 
differential.  
Lastly, generalizability across Canada should be taken cautiously. This is because the 
data source was limited to Ontario and New Brunswick participants. However, the population in 
those two provinces makes up nearly 40% of the Canadian population.141  
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Chapter 6  
6.1 Implications and further research 
This study examined and quantified the impact of not having PMCC on adherence in 
Canada overtime. The study assists in filling the knowledge gap for identifying if the absence of 
PMCC is associated with medication non-adherence among patients with HTN and DM type II. 
The results help in understanding the size of the “access gap” Canadians experience when they 
are unable to afford their chronic disease medications due to the absence of insurance to cover 
their prescription medication cost.37  
Because this study could use data from Ontario and New Brunswick only, further 
research is needed for a Canada-wide inclusion. What is now required is a longitudinal study 
involving this study’s participants to assess the change of adherence within the same 
individuals in order to examine the consistency of the current study’s findings. Moreover, a 
longitudinal study is also needed to measure the hazard of exposure to not having PMCC on 
facing clinical outcomes.  
This research has raised many questions in need of further investigation. Studies have 
found that people sometimes under-report their insurance status.139 It would be interesting to 
find out why seniors in Ontario have answered “no” to having PMCC. Finally, Ontario has 
recently introduced a new drug coverage policy. Effective January 2018, residents aged less 
than 25 years have been included in the provincial coverage plan, similar to the seniors’ plan. It 
is important to study the effect of policy implementation to measure the benefit of new 
 [52] 
 
coverage and whether it will cause improvement in their parents’ medication adherence for HT 
and DM. 
6.2 Conclusion 
The purpose of the current study was to investigate the trend and impact of not having 
PMCC on adherence to oral medication for hypertension and diabetes mellitus. Absence of 
PMCC increased slightly over the study period in Canada and the analysis revealed that 
absence of PMCC reduces the odds of adherence by 23%. This percentage reduction is 
consistent with previous research.137 However, the current study provides specific evidence 
about the impact of PMCC on adherence to the most devastating chronic diseases in 
Canada. This study also found that adherence improved over time in Canada, despite the 
increase of the proportion of people without PMCC. However, patients without PMCC did not 
take the full advantage of adherence improvement.  
One of the significant findings of this study is that the OR of adherence without PMCC 
remained fairly in between 0.7-0.8, even in subgroups stratified by age, by province, and by 
household income level. The evidence from this study also suggests that having more than one 
PMCC can improve adherence further by 44%.  Overall, this study provides the necessary real-
world evidence for the argument that PMCC is indeed needed for the improvement of 
adherence to oral hypertension and diabetes oral medications. The trend in this study also 
establishes that absence of PMCC still persists as a barrier hindering proper adherence to 
medications. 
  
 [53] 
 
References 
1. Mendis S, Armstrong T, Bettcher D, et al. Global status report on noncommunicable diseases 
2014. 
2. Remington P, Brownson R, Wegner M. Chronic disease epidemiology and control. 3rd ed. 
United States of America: American Public Health Association; 2010. ISBN-13: 978-0-87553-192-
2. 
3. Daskalopoulou SS, Rabi DM, Zarnke KB, et al. The 2015 Canadian hypertension education 
program recommendations for blood pressure measurement, diagnosis, assessment of risk, 
prevention, and treatment of hypertension. Can J Cardiol. 2015;31(5):549-568. 
4. Leung AA, Daskalopoulou SS, Dasgupta K, et al. Hypertension Canada's 2017 guidelines for 
diagnosis, risk assessment, prevention, and treatment of hypertension in adults. The Canadian 
journal of cardiology JID - 8510280. 0802(0828-282). 
5. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Goldenberg R, 
Punthakee Z. Definition, classification and diagnosis of diabetes, prediabetes and metabolic 
syndrome. Can J Diabetes. 2013;37 Suppl 1:S8-11. 
6. Canadian Diabetes Association, Québec D. Diabetes: Canada at the tipping point: Charting a 
new path. Canadian Diabetes Association; 2011. 
7. Weaver CG, Clement FM, Campbell NR, et al. Healthcare costs attributable to hypertension: 
Canadian population-based cohort study. Hypertension. 2015;66(3):502-508. 
 [54] 
 
8. Public Health Agency of Canada. Report from the Canadian chronic disease surveillance 
system: Hypertension in Canada, 2010. 2010. 
9. Sabaté E. Adherence to long-term therapies: Evidence for action. World Health Organization; 
2003. 
10. McQueen DV. Continuing efforts in global chronic disease prevention. Preventing Chronic 
Disease. 2007;4(2):A21. 
11. Robinson K, Farmer T, Elliott SJ, Eyles J. From heart health promotion to chronic disease 
prevention: Contributions of the Canadian heart health initiative. Prev Chronic Dis. 
2007;4(2):A29. 
12. Cummings KM, Kirscht JP, Binder LR, Godley AJ. Determinants of drug treatment 
maintenance among hypertensive persons in inner city detroit. Public Health Rep. 
1982;97(2):99-106. 
13. Calkins E, Boult C, Wagner E, Pacala J, eds. New ways to care for older people: Building 
systems based on evidence. Springer Publishing Company; 2004. 
14. Norris SL, Nichols PJ, Caspersen CJ, et al. The effectiveness of disease and case management 
for people with diabetes. A systematic review. Am J Prev Med. 2002;22(4 Suppl):15-38. 
15. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304-
314. 
 [55] 
 
16. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: A review 
from the patient's perspective. Ther Clin Risk Manag. 2008;4(1):269-286. 
17. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult 
population. results from the third national health and nutrition examination survey, 1988-1991. 
Hypertension. 1995;25(3):305-313. 
18. Farmer KC. Methods for measuring and monitoring medication regimen adherence in 
clinical trials and clinical practice. Clin Ther. 1999;21(6):1074-1090. 
19. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497. 
20. Martin LR, Williams SL, Haskard KB, Dimatteo MR. The challenge of patient adherence. Ther 
Clin Risk Manag. 2005;1(3):189-199. 
21. Ofori SN, Unachukwu CN. Holistic approach to prevention and management of type 2 
diabetes mellitus in a family setting. Diabetes, Metabolic Syndrome and Obesity: Targets and 
Therapy. 2014;7:159-168. 
22. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee 
on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. 
JAMA. 2003;289(19):2560-2571. 
23. Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining 
adherence to medications. Br J Clin Pharmacol. 2012;73(5):691-705. 
 [56] 
 
24. Garcia-Perez LE, Alvarez M, Dilla T, Gil-Guillen V, Orozco-Beltran D. Adherence to therapies 
in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175-194. 
25. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical 
treatment outcomes: A meta-analysis. Med Care. 2002;40(9):794-811. 
26. Vik SA, Hogan DB, Patten SB, Johnson JA, Romonko-Slack L, Maxwell CJ. Medication 
nonadherence and subsequent risk of hospitalisation and mortality among older adults. Drugs 
Aging. 2006;23(4):345-356. 
27. Wetzels GE, Nelemans P, Schouten JS, Prins MH. Facts and fiction of poor compliance as a 
cause of inadequate blood pressure control: A systematic review. J Hypertens. 
2004;22(10):1849-1855. 
28. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported 
measure of medication adherence. Med Care. 1986;24(1):67-74. 
29. Gellad WF, Grenard J, McGlynn EA. A review of barriers to medication adherence: A 
framework for driving policy options. RAND; 2009. 
30. Lam WY, Fresco P. Medication adherence measures: An overview. BioMed Research 
International. 2015;2015:217047. 
31. DiMatteo MR. Variations in patients' adherence to medical recommendations: A 
quantitative review of 50 years of research. Med Care. 2004;42(3):200-209. 
 [57] 
 
32. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs--do 
rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 
1995;332(17):1125-1131. 
33. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication 
taken as prescribed? A novel assessment technique. JAMA. 1989;261(22):3273-3277. 
34. Vitolins MZ, Rand CS, Rapp SR, Ribisl PM, Sevick MA. Measuring adherence to behavioral 
and medical interventions. Control Clin Trials. 2000;21(5 Suppl):188S-94S. 
35. Haynes RB, Taylor DW, Sackett DL, Gibson ES, Bernholz CD, Mukherjee J. Can simple clinical 
measurements detect patient noncompliance? Hypertension. 1980;2(6):757-764. 
36. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to 
antiretroviral therapy are consistent with electronic data and virological treatment outcome. 
AIDS. 2002;16(2):269-277. 
37. Law MR, Cheng L, Dhalla IA, Heard D, Morgan SG. The effect of cost on adherence to 
prescription medications in Canada. CMAJ. 2012;184(3):297-302. 
38. Lima-Costa MF, Peixoto SV, Firmo JOA. Validity of self-reported hypertension and its 
determinants (the bambuí study). Rev Saude Publica. 2004;38(5):637-642. 
39. Drieling RL, LaCroix AZ, Beresford SAA, Boudreau DM, Kooperberg C, Heckbert SR. Validity 
of self-reported medication use compared with pharmacy records in a cohort of older women: 
Findings from the women's health initiative. Am J Epidemiol. 2015;184(3):233-238. 
 [58] 
 
40. Gonzalez JS, Schneider HE, Wexler DJ, et al. Validity of medication adherence self-reports in 
adults with type 2 diabetes. Diabetes Care. 2013;36(4):831. 
41. Fletcher SW, Pappius EM, Harper SJ. Measurement of medication compliance in a clinical 
setting. comparison of three methods in patients prescribed digoxin. Arch Intern Med. 
1979;139(6):635-638. 
42. Turner BJ, Hecht FM. Improving on a coin toss to predict patient adherence to medications. 
Ann Intern Med. 2001;134(10):1004-1006. 
43. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures 
of antiretroviral therapy adherence: A review with recommendations for HIV research and 
clinical management. AIDS Behav. 2006;10(3):227-245. 
44. DiMatteo MR DD. Achieving patient compliance. New York: Pergamon; 1982. 
45. Norell SE. Accuracy of patient interviews and estimates by clinical staff in determining 
medication compliance. Soc Sci Med E. 1981;15(1):57-61. 
46. Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral 
adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S79-87. 
47. Rand C. "I took the medicine like you told me, doctor": Self-reports of adherence with 
medical regimens. In: Stone A, Turkkan J, Bachrach C, Jobe J, Kurtzman H, Cain V, eds. The 
science of self-report: Implications for research and practice. Mahwah, NJ: Lawrence Erlbaum 
Associates Inc.; 2000:257-276. 
 [59] 
 
48. Matsui D, Hermann C, Klein J, Berkovitch M, Olivieri N, Koren G. Critical comparison of novel 
and existing methods of compliance assessment during a clinical trial of an oral iron chelator. J 
Clin Pharmacol. 1994;34(9):944-949. 
49. Rudd P, Byyny RL, Zachary V, et al. The natural history of medication compliance in a drug 
trial: Limitations of pill counts. Clin Pharmacol Ther. 1989;46(2):169-176. 
50. Vik SA, Maxwell CJ, Hogan DB, Patten SB, Johnson JA, Romonko-Slack L. Assessing 
medication adherence among older persons in community settings. Can J Clin Pharmacol. 
2005;12(1):e152-e164. 
51. Rudd P, Byyny RL, Zachary V, et al. Pill count measures of compliance in a drug trial: 
Variability and suitability. Am J Hypertens. 1988;1(3 Pt 1):309-312. 
52. Pullar T, Kumar S, Tindall H, Feely M. Time to stop counting the tablets? Clin Pharmacol 
Ther. 1989;46(2):163-168. 
53. Bova CA, Fennie KP, Knafl GJ, Dieckhaus KD, Watrous E, Williams AB. Use of electronic 
monitoring devices to measure antiretroviral adherence: Practical considerations. AIDS Behav. 
2005;9(1):103-110. 
54. Wendel CS, Mohler MJ, Kroesen K, Ampel NM, Gifford AL, Coons SJ. Barriers to use of 
electronic adherence monitoring in an HIV clinic. Ann Pharmacother. 2001;35(9):1010-1015. 
55. Dirks JF, Kinsman RA. Nondichotomous patterns of medication usage: The yes-no fallacy. 
Clin Pharmacol Ther. 1982;31(4):413-417. 
 [60] 
 
56. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern 
Med. 1990;150(7):1509-1510. 
57. Haynes R, Montague P, Oliver T, McKibbon K, Brouwers M, Kanani R. Interventions for 
helping patients follow prescriptions for medications. The Cochrane Library. 2001. 
58. Sackett DL, Haynes RB, Gibson ES, Taylor DW, Roberts RS, Johnson AL. Patient compliance 
with antihypertensive regimens. Patient Couns Health Educ. 1978;1(1):18-21. 
59. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin 
Ther. 1998;20(4):671-681. 
60. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW, Stang MR, Semchuk WM. Adherence to 
statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first 
cardiovascular event: A retrospective cohort study. Can J Cardiol. 2005;21(6):485-488. 
61. Fischer MA, Stedman MR, Lii J, et al. Primary medication non-adherence: Analysis of 
195,930 electronic prescriptions. J Gen Intern Med. 2010;25(4):284-290. 
62. Tamblyn R, Eguale T, Huang A, Winslade N, Doran P. The incidence and determinants of 
primary nonadherence with prescribed medication in primary Care A cohort Study Primary 
nonadherence with prescribed medication in primary care. Annals of Internal Medicine. 
2014;160(7):441-450. 
63. World Health Organization. The pursuit of responsible use of medicines: Sharing and 
learning from country experiences. 2012. 
 [61] 
 
64. Iuga AO, McGuire MJ. Adherence and health care costs. Risk Manag Healthc Policy. 
2014;7:35-44. 
65. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-
specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual 
data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-1913. 
66. Aitken M, Valkova S. Avoidable costs in US healthcare: the $200 billion opportunity from 
using medicines . IMS Institute for Healthcare Informatics, Parsippany, NJ. 2013. 
67. AlGhurair SA, Hughes CA, Simpson SH, Guirguis LM. A systematic review of patient self-
reported barriers of adherence to antihypertensive medications using the world health 
organization multidimensional adherence model. J Clin Hypertens (Greenwich). 
2012;14(12):877-886. 
68. Lexchin J, Grootendorst P. Effects of prescription drug user fees on drug and health services 
use and on health status in vulnerable populations: A systematic review of the evidence. Int J 
Health Serv. 2004;34(1):101-122. 
69. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: Associations with 
medication and medical utilization and spending and health. JAMA. 2007;298(1):61-69. 
70. Daw JR, Morgan SG. Stitching the gaps in the Canadian public drug coverage patchwork?: A 
review of provincial Pharmacare policy changes from 2000 to 2010. Health Policy. 
2012;104(1):19-26. 
 [62] 
 
71. Lovish D, Lubkeman M, Roeslund T. The Hidden Epidemic Finding a Cure for Unfilled 
Prescriptions and Missed Doses.2003.Boston Consulting Group.  
72. Kennedy J, Tuleu I, Mackay K. Unfilled prescriptions of medicare beneficiaries: Prevalence, 
reasons, and types of medicines prescribed. J Manag Care Pharm. 2008;14(6):553-560. 
73. Rybacki JJ. Improving cardiovascular health in postmenopausal women by addressing 
medication adherence issues. J Am Pharm Assoc (Wash). 2002;42(1):63-71; quiz 72-3. 
74. McLean W. Medication adherence initiatives — part I. Canadian Pharmacists Journal. 
2007;140(4):254-261. 
75. Canadian Institute for Health Information. Drivers of prescription drug spending in Canada - 
CIHI. 2012. 
76. Morgan SG, Law M, Daw JR, Abraham L, Martin D. Estimated cost of universal public 
coverage of prescription drugs in Canada. CMAJ. 2015;187(7):491-497. 
77. Marchildon GP. Health systems in transition: Canada. Marchildon GP. Health Systems in 
Transition: Canada. Copenhagen, WHO Regional Office for Europe on behalf of the European 
Observatory on Health Systems and Policies. 2005;7(3). 
78. Coombes ME, Morgan SG, Barer ML, Pagliccia N. Who's the fairest of them all? which 
provincial Pharmacare model would best protect Canadians against catastrophic drug costs? 
Healthcare Quarterly. 2004;7(4). 
 [63] 
 
79. Morgan S, Daw J, Law M. Rethinking Pharmacare in Canada. Commentary_384.pdf. 2013. 
80. Expanding Coverage to Include Protection Against Catastrophic Prescription Drug Costs. 
PARLIAMENT of CANADA. 
http://www.parl.gc.ca/content/sen/committee/372/soci/rep/repoct02vol6part3-e.htm. 
Accessed October 7, 2016. 
81. Phillips K. Catastrophic drug coverage in Canada. Library of Parliament;Bibliothèque du 
Parlement; 2016. https://lop.parl.ca/Content/LOP/ResearchPublications/2016-10-e.pdf 
82. Anis AH, Guh D, Wang X. A dog's breakfast: Prescription drug coverage varies widely across 
Canada. Med Care. 2001;39(4):315-326. 
83. Kapur V, Basu K. Drug coverage in Canada: Who is at risk? Health Policy. 2005;71(2):181-
193. 
84. Demers V, Melo M, Jackevicius C, et al. Comparison of provincial prescription drug plans and 
the impact on patients' annual drug expenditures. CMAJ. 2008;178(4):405-409. 
85. Gee ME, Campbell NR, Gwadry-Sridhar F, et al. Antihypertensive medication use, 
adherence, stops, and starts in Canadians with hypertension. Can J Cardiol. 2012;28(3):383-389. 
86. Gouvernement du Québec. Prescription drug coverage.  Re´gie de l’Assurance Maladie du 
Que´bec (provincial insurance agency) Web site. 
http://www.ramq.gouv.qc.ca/en/citizens/prescription-drug-insurance/Pages/eligibility.aspx. 
Accessed June, 2016. 
 [64] 
 
87. Soumerai SB, Pierre-Jacques M, Zhang F, et al. Cost-related medication nonadherence 
among elderly and disabled medicare beneficiaries: A national survey 1 year before the 
medicare drug benefit. Arch Intern Med. 2006;166(17):1829-1835. 
88. Briesacher BA, Gurwitz JH, Soumerai SB. Patients at-risk for cost-related medication 
nonadherence: A review of the literature. J Gen Intern Med. 2007;22(6):864-871. 
89. Madden JM, Graves AJ, Zhang F, et al. Cost-related medication nonadherence and spending 
on basic needs following implementation of Medicare part D. JAMA. 2008;299(16):1922-1928. 
90. Canadian Pharmacists Association. PRINCIPLES & PRIORITIES Pharmacare 2.0. 
http://www.pharmacists.ca/cpha-ca/assets/File/cpha-on-the-
issues/Pharmacare%20Principles%20and%20Priorities%20Discussion%20Paper.pdf. Accessed 
October 7th, 2016. 
91. Patten SB. Epidemiology for Canadian students: Principles, methods and critical appraisal . 
Canada: Brush Education Inc.; 2015. 
92. Statistics Canada. Canadian community health survey - annual component (CCHS). 
http://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&SDDS=3226#a3. Updated 
April, 2015. Accessed March, 2016, ,2016. 
93. Statistics Canada. Canadian community health survey (CCHS) 2008 questionnaire. 2008. 
94. Allin S, Bayoumi AM, Law MR, Laporte A. Comparability of self-reported medication use and 
pharmacy claims data. Health Rep. 2013;24(1):3-9. 
 [65] 
 
95. Statistics Canada. Canadian community health survey (CCHS) annual component user guide 
2010 and 2009-2010 microdata files. 2011. 
96. Sarafin C, Simard M, Thomas S. A review of the weighting strategy for the Canadian 
community health survey. 2007. 
97. Cox BG, Binder DA, Chinnappa BN, Christianson A, Colledge MJ, Kott PS. Business survey 
methods. Vol 214. John Wiley & Sons; 2011. 
98. Chatrchi G. The impact of typical survey weighting adjustments on the design effect: A case 
study. Survey Methods: Insights from the Field (SMIF). 2015. 
99. Last J, ed. A dictionary of epidemiology. 3rd ed. New York, NY: Oxford University Press; 
1995. 
100. Statistics Canada. Canadian community health survey (CCHS) annual component - public 
use microdata file, 2014 derived variable (DV) specifications. 2014. 
101. Statistics Canada. Canadian community health survey (CCHS) 2007 questionnaire. 2007. 
102. Shao J. Impact of the bootstrap on sample surveys. Statistical Science. 2003;18(2):191-198. 
103. National Center for Health Statistics and Statistics Canada. The Joint Canada/United States 
survey of health. 2004. 
104. Kennedy J, Morgan S. A cross-national study of prescription nonadherence due to cost: 
Data from the joint Canada-United States survey of health. Clin Ther. 2006;28(8):1217-1224. 
 [66] 
 
105. Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Chapter 1: Epidemiology of type 1 
diabetes. Endocrinol Metab Clin North Am. 2010;39(3):481-497. 
106. Statistics Canada. Canadian community health survey (CCHS) annual component - 2013 
questionnaire. 2013. 
107. Statistics Canada. Canadian community health survey (CCHS) annual component - 2014 
questionnaire. 2015. 
108. Ng E, Dasgupta K, Johnson JA. An algorithm to differentiate diabetic respondents in the 
Canadian community health survey. Health Rep. 2008;19(1):71-79. 
109. Yeung C, Thomas S. Income imputation for the Canadian community health survey. April 
2013. http://publications.gc.ca/collections/collection_2017/statcan/11-613/CS11-619-2013-3-
eng.pdf. 
110. Income Statistics Division. Low income lines, 2013-2014: Update. December 17, 2015(002). 
111. Thomas S, Wannell B. Combining cycles of the Canadian community health survey. Health 
Rep. 2009;20(1):53-58. 
112. Oremus M. Measures of association and impact: Lecture 7. 2016. 
113. Lengerich E. 3.5 - bias, confounding and effect modification. Penn State Science — Eberly 
College of Science Web site. https://onlinecourses.science.psu.edu/stat507/node/34. Updated 
2017November, 2017. 
 [67] 
 
114. Dormann CF, Elith J, Bacher S, et al. Collinearity: A review of methods to deal with it and a 
simulation study evaluating their performance. Ecography. 2013;36(1):27-46. 
115. Mukaka MM. A guide to appropriate use of correlation coefficient in medical research. 
Malawi Medical Journal : The Journal of Medical Association of Malawi. 2012;24(3):69-71. 
116. Berglund P. Multiple imputation using the fully conditional specification method: A 
comparison of SAS®, STATA®, IVEware, and R. 2015:2081-2015. 
117. Hoover M, Rotermann M, Sanmartin C, Bernier J. Validation of an index to estimate the 
prevalence of frailty among community-dwelling seniors. Health Rep. 2013;24(9):10-17. 
118. Wen CP, Tsai SP. Anatomy of the health worker effect - a critique of summary statistics 
employed in occupational epidemiology. Scand J Work Environ Health. 1982;8 Suppl 1:48-52. 
119. Campbell NR, So L, Amankwah E, Quan H, Maxwell C, Canadian Hypertension Education 
Program Outcomes Research Task Force. Characteristics of hypertensive Canadians not 
receiving drug therapy. Can J Cardiol. 2008;24(6):485-490. 
120. Ontario- Ministry of Health and Long Term Care. Get coverage for prescription drugs. 
https://www.ontario.ca/page/get-coverage-prescription-drugs#section-0. Updated February 5, 
2018. Accessed February 13, 2018, September 20, 2016. 
121. Government of New Brunswick. New Brunswick drug plans for seniors. Health Web site. 
http://fetenbday.gnb.ca/content/gnb/en/services/services_renderer.8875.New_Brunswick_Dr
ug_Plans_for_Seniors.html. Updated 2018. Accessed February, 2018. 
 [68] 
 
122. Government of New Brunswick. NB drug plans & Medavie Blue Cross seniors’ health 
program. 2018(January). 
123. Lyles RH, Lin J. Sensitivity analysis for misclassification in logistic regression via likelihood 
methods and predictive value weighting. Stat Med. 2010;29(22):2297-2309. 
124. Allison PD. Missing data: Quantitative applications in the social sciences. Vol 55. Wiley 
Online Library; 2002:193-196. 
125. Sterner WR. What is missing in counseling research? reporting missing data. Journal of 
Counseling & Development. 2011;89(1):56-62. 
126. Canadian Institute for Health Information. National health expenditure trends, 1975 to 
2010. 2010. 
127. Canadian Institute for Health Information. National health expenditure trends, 1975 to 
2014. 2014. 
128. Canadian Institute for Health Information. Drug expenditure in Canada, 1985 to 2007. 
2008. 
129. Sanmartin C, Hennessy D, Lu Y, Law MR. Trends in out-of-pocket health care expenditures 
in Canada, by household income, 1997 to 2009. Health reports. 2014;25(4):13. 
130. Yu B, Zhang X, Wang G. Full coverage for hypertension drugs in rural communities in china. 
Am J Manag Care. 2013;19(1):e22-e29. 
 [69] 
 
131. Rao CR, Kamath VG, Shetty A, Kamath A. Treatment compliance among patients with 
hypertension and type 2 diabetes mellitus in a coastal population of Southern India. Int J Prev 
Med. 2014;5(8):992-998. 
132. Natarajan N, Putnam W, Van Aarsen K, Beverley Lawson K, Burge F. Adherence to 
antihypertensive medications among family practice patients with diabetes mellitus and 
hypertension. Can Fam Physician. 2013;59(2):e93-e100. 
133. Rolnick SJ, Pawloski PA, Hedblom BD, Asche SE, Bruzek RJ. Patient characteristics 
associated with medication adherence. Clin Med Res. 2013;11(2):54-65. 
134. Shin DW, Park JH, Park JH, et al. Antihypertensive medication adherence in cancer 
survivors and its affecting factors: Results of a Korean population-based study. Support Care 
Cancer. 2010;19(2):211-220. 
135. Choudhry NK, Setoguchi S, Levin R, Winkelmayer WC, Shrank WH. Trends in adherence to 
secondary prevention medications in elderly post-myocardial infarction patients. 
Pharmacoepidemiol Drug Saf. 2008;17(12):1189-1196. 
136. DiMatteo MR, FAU HK, Williams SL. Health beliefs, disease severity, and patient 
adherence: A meta-analysis. Medical care JID - 0230027. 2007. 
137. Gai Y., Gu NY. Association between insurance gaps and continued antihypertension 
medication usage in a US national representative population. American Journal of Hypertension. 
2009;22(12):1276-1280. 
 [70] 
 
138. Kelsey JL. Methods in observational epidemiology. Vol 26. Oxford University Press, USA; 
1986. 
139. Grootendorst P, Newman EC, Levine MA. Validity of self-reported prescription drug 
insurance coverage. Health Rep. 2003;14(2):35-46. 
140. Padwal RS, Bienek A, McAlister FA, Campbell NR, Outcomes Research Task Force of the 
Canadian Hypertension Education Program. Epidemiology of hypertension in Canada: An 
update. Can J Cardiol. 2016;32(5):687-694. 
141. Statistics Canada. Census profile, 2016 census. 2016.  
 
   
 [71] 
 
 Appendix A   
Figure 5: Steps taken to achieve study participants (unweighted). 
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month oral medication use for either Diabetes Mellitus (DM) 
or Hypertension (HTN) (i.e. the adherence indicator question) 
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Figure 6: Steps taken to achieve study participants (weighted). 
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Appendix B 
Table 12-Characteristics of respondents in study  
Variable Name Categories 
No Insurance 
(n=4329) 
Insurance (n=18886) Total (n=23215) P-Value from Chi-Square or t-test 
    n % n % n %   
Adherence 
(Outcome) 
Yes 3037 70.15 14616 77.39 17653 76.04 
<0.0001 No 1292 29.85 4270 22.61 5562 23.96 
Total 4329 100.00 18886 100.00 23215 100.00 
Year 
  2007 or 2008  1547 35.74 6472 34.27 8019 34.54 
0.0994 
2013 1418 32.76 6180 32.72 7598 32.73 
2014 1364 31.51 6234 33.01 7598 32.73 
Total 4329 100.00 18886 100.00 23215 100.00 
Age 
Mean (SD) 63.81  (14.865) 64.98 (13.77) 64.76 (13.99) <0.0001 
18-29 141 3.26 272 1.44 413 1.78 
<0.0001 
30-44 328 7.58 1357 7.19 1685 7.26 
45-64 1707 39.43 6865 36.35 8572 36.92 
65+ 2153 49.73 10392 55.02 12545 54.04 
Total 4329 100.00 18886 100.00 23215 100.00 
Minimum Age 18     
Maximum Age 102 104     
SEX 
Male  1841 42.53 8420 44.58 10261 44.20 
0.0140 Female 2488 57.47 10466 55.42 12954 55.80 
Total   100.00   100.00 23215 100.00 
Education Level 
Less than 
Secondary School 
graduation  
1421 32.83 5029 26.63 6450 27.78 
<0.0001 Secondary School 
Graduation 
880 20.33 3852 20.40 4732 20.38 
Secondary School 
Graduation 
2028 46.85 10005 52.98 12033 51.83 
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Variable Name Categories 
No Insurance 
(n=4329) 
Insurance (n=18886) Total (n=23215) P-Value from Chi-Square or t-test 
Total 4329 100.00 18886 100.00 23215 100.00 
Household 
Income (National 
level quintiles) 
First 20% (Lowest 
Income) 
1410 32.57 3866 20.47 5276 22.73 
<0.0001 
Second 20%  1373 31.72 4466 23.65 5839 25.15 
Third 20%  746 17.23 3898 20.64 4644 20.00 
Fourth 20% 451 10.42 3507 18.57 3958 17.05 
Fifth 20%(Highest 
Income) 
349 8.06 3149 16.67 3498 15.07 
Total 4329 100.00 18886 100.00 23215 100.00 
Number of 
chronic diseases 
Hypertension or 
diabetes 
3596 83.07 15223 80.60 18819 81.06 
0.0002 Hypertension and 
diabetes 
733 16.93 3663 19.40 4396 18.94 
Total 4329 100.00 18886 100.00 23215 100.00 
Province 
Ontario 3541 81.80 16073 85.11 19614 84.49 
<.0001 New Brunswick 788 18.20 2813 14.89 3601 15.51 
Total 4329 100.00 18886 100.00 23215 100.00 
Race 
Aboriginal 113 2.61 589 3.12 702 3.02 
<0.0001 
White 3807 87.94 17058 90.32 20865 89.88 
Other 409 9.45 1239 6.56 1648 7.10 
Total 4329 100.00 18886 100.00 23215 100.00 
Smoking status 
Smoker 852 19.68 2952 15.63 3804 16.39 
<0.0001 Non-smoker 3477 80.32 15934 84.37 19411 83.61 
Total 4329 100.00 18886 100.00 23215 100.00 
Alcohol 
consumption  
Regular drinker 2120 48.97 9873 52.28 11993 51.66 
<0.0001 
Occasional drinker 835 19.29 3637 19.26 4472 19.26 
Did not drink in 
the last 12 months 
1374 31.74 5376 28.47 6750 29.08 
Total 4329 100.00 18886 100.00 23215 100.00 
Hypertension 3262 75.35 13822 73.19 17084 73.59 0.0009 
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Variable Name Categories 
No Insurance 
(n=4329) 
Insurance (n=18886) Total (n=23215) P-Value from Chi-Square or t-test 
Disease of 
interest 
Diabetes 334 7.72 1401 7.42 1735 7.47 
Both DM and HTN 733 16.93 3663 19.40 4396 18.94 
Total 4329 100.00 18886 100.00 23215 100.00 
Asthma 
Yes 377 8.71 1745 9.24 2122 9.14 
0.2742 No 3952 91.29 17141 90.76 21093 90.86 
Total 4329 100.00 18886 100.00 23215 100.00 
Arthritis 
(arthritis, 
excluding 
fibromyalgia) 
Yes 1725 39.85 8247 43.67 9972 42.95 
<.0001 
No 2604 60.15 10639 56.33 13243 57.05 
Total 4329 100.00 18886 100.00 23215 100.00 
Back Problems 
Yes 1297 29.96 5858 31.02 7155 30.82 
0.1743 No 3032 70.04 13028 68.98 16060 69.18 
Total 4329 100.00 18886 100.00 23215 100.00 
Migraine 
Yes 408 9.42 1684 8.92 2092 9.01 
0.2923 No 3921 90.58 17202 91.08 21123 90.99 
Total 4329 100.00 18886 100.00 23215 100.00 
Cardiovascular 
Disease (Heart 
disease/stroke) 
Yes 720 16.63 3747 19.84 4467 19.24 
<.0001 No 3609 83.37 15139 80.16 18748 80.76 
Total 4329 100.00 18886 100.00 23215 100.00 
Cancer 
Yes 643 14.85 3220 17.05 3863 16.64 
0.0005 No 3686 85.15 15666 82.95 19352 83.36 
Total 4329 100.00 18886 100.00 23215 100.00 
Gastrointestinal: 
ulcer or have a 
bowel disorder 
such as Crohn’s 
Disease, 
ulcerative colitis, 
Irritable Bowel 
Syndrome or 
Yes 503 11.62 2082 11.02 2585 11.14 
0.2614 
No 3826 88.38 16804 88.98 20630 88.86 
Total 4329 100.00 18886 100.00 23215 100.00 
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Variable Name Categories 
No Insurance 
(n=4329) 
Insurance (n=18886) Total (n=23215) P-Value from Chi-Square or t-test 
bowel 
incontinence 
Mental health 
YES 588 13.58 2845 15.06 3433 14.79 
0.0133 NO 3741 86.42 16041 84.94 19782 85.21 
Total 4329 100.00 18886 100.00 23215 100.00 
Staying overnight 
in hospital, 
nursing home or 
convalescent 
home 
Yes 517 2.23 2552 13.51 3069 13.22 
0.0059 
No 3812 88.06 16334 86.49 20146 86.78 
Total 4329 90.28 18886 100.00 23215 100.00 
Main source of 
Household 
income 
Employment 
(history) 
3369 77.82 15481 81.97 18850 81.20 
<.0001 
Governmental 
support 
427 9.86 1696 8.98 2123 9.14 
Other 525 12.13 1696 8.98 2221 9.57 
Total 4321 99.82 18873 99.93 23194 99.91 
General health 
perception 
Good 3210 74.15 13936 73.79 17146 73.86 
0.2157 
fair 767 17.72 3519 18.63 4286 18.46 
poor 352 8.13 1431 7.58 1783 7.68 
Total 4329 100.00 18886 100.00 23215 100.00 
Has taken flu shot  
Yes 3085 71.26 14833 78.54 17918 77.18 
<.0001 No 1244 28.74 4053 21.46 5297 22.82 
 Total 4329 100.00 18886 100.00 23215 100.00 
Has regular 
medical doctor 
Yes 4075 94.13 18165 96.18 22240 95.80 
<.0001 No 254 5.87 721 3.82 975 4.20 
Total 4329 100.00 18886 100.00 23215 100.00 
SUB SAMPLE: 
Health insurance 
plan type 
 Government _ _ 7282 38.56 7282 31.37 
<.0001 
Employer/private _ _ 10310 54.59 10310 44.41 
Mixed _ _ 1215 6.43 1215 5.23 
Total 18807 99.58 18807 81.01 
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Table 13 Characteristics of study sample (Weighted) 
Variable Name Categories No Insurance (n=1735362) Insurance (n=6961158) Total (n=8696520) 
P-Value 
from Chi-
Square or 
t-test 
    n % n % n %   
Adherence 
(Outcome) 
Yes 1135543 65.44 5112279 73.44 6247822 71.84 
<0.0001 No 599818 34.56 1848880 26.56 2448698 28.16 
Total 1735361 100 6961159 100 8696520 100 
Year 
  2007 or 2008  530789 30.59 2182171 31.35 2712960 31.20 
0.0994 2013 585180 33.72 2401508 34.50 2986688 34.34 
2014 619393 35.69 2377479 34.15 2996872 34.46 
Total 1735362 100.00 6961158 100.00 8696520 100.00 
Age 
Mean (SD) 58.34  (2829429) 60.5 (4874214) 60.07 (5328763)   
18-29 81559 4.70 169245 2.43 250804 2.88 
<0.0001 
30-44 232957 13.42 797236 11.45 1030193 11.85 
45-64 828879 47.76 3135195 45.04 3964074 45.58 
65+ 591967 34.11 2859482 41.08 3451449 39.69 
Total 1735362 100.00 6961158 100.00 8696520 100.00 
Minimum Age 18     
Maximum Age 102 104     
SEX 
Male  862618 49.71 3588107 51.54 4450725 51.18 
0.2725 Female 872744 50.29 3373051 48.46 4245795 48.82 
Total 1735362 100.00 6961158 100.00 8696520 100.00 
Education Level 
Less than Secondary 
School graduation  
491818 28.34 1549046 22.25 2040864 23.47 
0.0001 
Secondary School 
Graduation 
330784 19.06 1441849 20.71 1772633 20.38 
Secondary School 
Graduation 
912759 52.60 3970263 57.03 4883022 56.15 
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Variable Name Categories No Insurance (n=1735362) Insurance (n=6961158) Total (n=8696520) 
P-Value 
from Chi-
Square or 
t-test 
Total 1735362 100.00 6961158 100.00 8696520 100.00 
Household 
Income (National 
level quintiles) 
First 20% (Lowest 
Income) 
620885 35.78 1358475 19.52 1979360 22.76 
<0.0001 Second 20%  497474 28.67 1472436 21.15 1969910 22.65 
Third 20%  274700 15.83 1402885 20.15 1677585 19.29 
Fourth 20% 188737 10.88 1394726 20.04 1583463 18.21 
Fifth 20%(Highest 
Income) 
153565 8.85 1332636 19.14 1486201 17.09 
Total 1735362 100.00 6961158 100.00 8696520 100.00 
Number of 
chronic diseases 
Hypertension or 
diabetes 
1492682 86.02 5714627 82.09 7207309 82.88 
0.0001 
Having both 
Hypertension and 
diabetes 
242680 13.98 1246531 17.91 1489211 17.12 
Total 1735362 100.00 6961158 100.00 8696520 100.00 
Province 
Ontario 1579895 91.04 6382477 91.69 7962372 91.56 
0.2310 New Brunswick 155467 8.96 578681 8.31 734148 8.44 
Total 1735362 100.00 6961158 100.00 8696520 100.00 
Race 
Aboriginal 38156 2.20 182038 2.62 220194 2.53 
<0.0001 White 1217862 70.18 5545839 79.67 6763701 77.77 
Other 479344 27.62 1233281 17.72 1712625 19.69 
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Variable Name Categories No Insurance (n=1735362) Insurance (n=6961158) Total (n=8696520) 
P-Value 
from Chi-
Square or 
t-test 
Total 1735362 100.00 6961158 100.00 8696520 100.00 
Smoking status 
Smoker 356442 20.54 1160917 16.68 1517359 17.45 
0.0017 Non-smoker 1378920 79.46 5800242 83.32 7179162 82.55 
Total 1735362 100.00 6961159 100.00 8696521 100.00 
Alcohol 
consumption  
Regular drinker 850563 49.01 3703465 53.20 4554028 52.37 
0.0063 
Occasional drinker 307775 17.74 1286596 18.48 1594371 18.33 
Did not drink in the 
last 12 months 
577024 33.25 1971097 28.32 2548121 29.30 
Total 1735362 100.00 6961158 100.00 8696520 100.00 
Disease of 
interest 
Hypertension 1317199 75.90 5129435 73.69 6446634 74.13 
0.0043 
Diabetes 175482 10.11 585192 8.41 760674 8.75 
Both DM and HTN 242680 13.98 1246531 17.91 1489211 17.12 
Total 1735361 100.00 6961158 100.00 8696519 100.00 
Asthma 
Yes 133295 7.68 637085 9.15 770380 8.86 
0.0615 No 1602067 92.32 6324074 90.85 7926141 91.14 
Total 1735362 100.00 6961159 100 8696521 100.00 
Arthritis (arthritis, 
excluding 
fibromyalgia) 
Yes 538656 31.04 2546995 36.59 3085651 35.48 
0.0002 No 1196706 68.96 4414163 63.41 5610869 64.52 
Total 1735362 100.00 6961158 100 8696520 100.00 
Back Problems 
Yes 482083 27.78 2009494 28.87 2491577 28.65 
0.4609 No 1253279 72.22 4951664 71.13 6204943 71.35 
Total 1735362 100.00 6961158 100 8696520 100.00 
Migraine 
Yes 174859 10.08 715959 10.29 890818 10.24 
0.8223 No 1560503 89.92 6245199 89.71 7805702 89.76 
Total 1735362 100.00 6961158 100 8696520 100.00 
Yes 216279 12.46 1175563 16.89 1391842 16.00 <.0001 
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Variable Name Categories No Insurance (n=1735362) Insurance (n=6961158) Total (n=8696520) 
P-Value 
from Chi-
Square or 
t-test 
Cardiovascular 
Disease (Heart 
disease/stroke) 
No 1519082 87.54 5785596 83.11 7304678 84.00 
Total 1735361 100.00 6961159 100 8696520 100.00 
Cancer 
Yes 184295 10.62 888076 12.76 1072371 12.33 
0.0532 No 1551066 89.38 6073082 87.24 7624148 87.67 
Total 1735361 100.00 6961158 100 8696519 100.00 
Gastrointestinal: 
ulcer or have a 
bowel disorder 
such as Crohn’s 
Disease, 
ulcerative colitis, 
Irritable Bowel 
Syndrome or 
bowel 
incontinence 
Yes 168173 9.69 717267 10.30 885440 10.18 
0.5456 
No 1567189 90.31 6243892 89.70 7811081 89.82 
Total 1735362 100.00 6961159 100 8696521 100.00 
Mental health 
YES 235704 13.58 1083352 15.56 1319056 15.17 
0.1145 NO 1499658 86.42 5877806 84.44 7377464 84.83 
Total 1735362 100.00 6961158 100 8696520 100.00 
Staying overnight 
in hospital, 
nursing home or 
convalescent 
home 
Yes 180599 10.41 803680 11.55 984279 11.32 
0.2878 No 1554763 89.59 6157478 88.45 7712241 88.68 
Total 1735362 100.00 6961158 100 8696520 100.00 
Main source of 
Household 
income 
Employment 
(history) 
1418460 81.74 5930548 85.19 7349008 84.51 
0.0107 
Governmental 
support 
144371 8.32 491159 7.06 635530 7.31 
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Variable Name Categories No Insurance (n=1735362) Insurance (n=6961158) Total (n=8696520) 
P-Value 
from Chi-
Square or 
t-test 
Other 171234 9.87 532488 7.65 703722 8.09 
Total 1734065.00 99.93 6954195 99.90 8688260 99.91 
General health 
perception 
Good 1277430 73.61 5208613 74.82 6486043 74.58 
0.4264 
fair 298529 17.20 1203994 17.30 1502523 17.28 
poor 159403 9.19 548552 7.88 707955 8.14 
Total 1735362 100.00 6961159 100.00 8696521 100.00 
Has taken flu shot  
Yes 1147902 66.15 5215517 74.92 6363419 73.17 
<.0001 No 587460 33.85 1745641 25.08 2333101 26.83 
 Total 1735362 100.00 6961158 100 8696520 100.00 
Has regular 
medical doctor 
Yes 1613692 92.99 6692340 96.14 8306032 95.51 
<.0001 No 121670 7.01 268818 3.86 390488 4.49 
Total 1735362 100.00 6961158 100 8696520 100.00 
SUB SAMPLE: 
Health insurance 
plan 
 Government-
sponsored 
_ _ 2269571 32.60 2269571 26.10 
<.0001 
Employer/private-
sponsored 
_ _ 4321788 62.08 4321788 49.70 
Mixed _ _ 350227 5.03 350227 4.03 
Total 6941586 99.72 6941586 79.82 
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Figure 7 Characteristics among respondents to the CCHS in 2007-2008, 2013, 2014  
1 2 3 4 1 2 3
Low
Income
Middle
Income
High
Income
Adherence No Insurance in Age Group
SEX
(females)
Eudcation level Income status
2007-2008 70.7% 6.6% 15.0% 47.1% 31.3% 50.2% 24.2% 17.6% 58.2% 23.4% 58.3% 18.3%
2013 71.4% 5.4% 10.7% 48.2% 35.7% 48.9% 24.1% 21.7% 54.2% 22.4% 59.9% 17.7%
2014 73.3% 2.5% 14.6% 47.9% 35.0% 47.5% 22.2% 21.6% 56.2% 22.5% 62.1% 15.4%
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Smoking No flu shot
Regular
doctor
Cancer CVD Both HT + DM Ontario
2007-2008 18.5% 24.4% 94.9% 12.4% 16.9% 16.0% 87.2%
2013 17.5% 29.3% 95.4% 13.0% 15.2% 17.1% 93.6%
2014 16.5% 26.6% 96.1% 11.6% 15.9% 18.2% 93.5%
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Figure 7 (Cont.)Characteristics among respondents to the CCHS in 2007-2008, 2013, 2014
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Figure 8 Characteristics among senior respondents with wrong perception of not having insurance in the CCHS in 2007-2008, 2013, 
2014 
 
1 2 3 Low Middle High
Adherenc
e
SEX
(females)
Eudcation level Income Smoking
No flu
shot
Regular
doctor
Cancer cvd
Both HT +
DM
Ontario
2007-2008 83.3% 58.4% 41.6% 16.6% 41.7% 36.2% 54.0% 9.9% 11.4% 20.2% 96.6% 20.6% 22.5% 16.9% 85.8%
2013 84.8% 56.1% 46.6% 17.9% 35.5% 35.4% 61.1% 3.5% 9.7% 21.9% 96.9% 20.4% 21.1% 19.2% 93.9%
2014 82.2% 59.5% 35.6% 21.2% 43.2% 35.9% 56.9% 7.1% 10.0% 19.6% 96.1% 16.0% 25.0% 25.2% 93.6%
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Appendix C 
Table 14: Results of full model output 
Effect 
Odds Ratio 
Estimates 
95% Wald 
Confidence Limits 
No Insurance vs. Insurance 0.774 0.657 0.911 
Ontario vs New Brunswick 1.016 0.891 1.159 
Female vs. male 0.844 0.742 0.96 
2013 vs. 2007-2008 0.998 0.844 1.18 
2014 vs. 2007-2008 1.053 0.908 1.221 
Secondary education vs. lower 1.131 0.922 1.388 
Post Secondary education vs. lower than 
secondary 
0.829 0.693 0.992 
30-44  vs 18-29 4.449 2.575 7.689 
45-64  vs 18-29 12.795 7.595 21.556 
65+ vs 18-29 25.479 15.078 43.056 
2nd vs. 1st quintile 1.150 0.953 1.388 
3rd vs. 1st quintile 1.012 0.817 1.255 
4th vs. 1st quintile 0.896 0.71 1.132 
5th vs. 1st quintile 0.984 0.791 1.225 
Smoking vs nonsmoking 0.696 0.586 0.827 
No flu shot vs. flu shot 0.725 0.625 0.841 
No regular doctor. vs. regular doctor 0.486 0.364 0.649 
1 disease  (HTN/DM) vs. both 1.273 1.071 1.513 
No cancer vs cancer 1.205 1.021 1.423 
No cardiovascular disease vs. cardiovascular 0.601 0.509 0.709 
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Appendix D 
 
Figure 9: Odds Ratios of Adherence with No Insurance in Subgroups in 95% Confidence Intervals 
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Table 15: Odds Ratios of Adherence with No Insurance in Subgroups in 95% Confidence 
Intervals. 
No Insurance vs. Insurance  Odds Ratio 
Estimates 
95% Wald 
Subgroups Confidence Limits 
Ontario 0.774 0.644 0.921 
New Brunswick 0.802 0.612 1.051 
Ontario ≥ 65 0.751 0.609 0.926 
New Brunswick ≥ 65 0.76 0.529 1.092 
Ontario-below 65 0.743 0.592 0.932 
New Brunswick-below 65 0.733 0.51 1.055 
Lowest Income (1st Quintile) 0.739 0.541 1.01 
Middle Income (2nd, 3rd, 4th Quintile) 0.804 0.659 0.980 
Highest Income (5th Quintile) 0.715 0.425 1.205 
Highest Income and age ≥ 65 years 0.958 0.378 2.428 
Highest Income and age ≥ 65 years- Ontario 0.930 0.362 2.388 
Highest Income and age < 65 years 0.599 0.356 1.006 
Highest Income and age < 65 years- Ontario 0.592 0.344 1.019 
Highest Income and age < 65 years- New Brunswick 1.121 0.075 16.775 
Middle Income and age ≥ 65 years 0.883 0.699 1.115 
Middle Income and age ≥ 65 years- Ontario 0.883 0.685 1.138 
Middle Income and age ≥ 65 years- New Brunswick  0.810 0.441 1.489 
Middle Income and age < 65 years 0.805 0.632 1.026 
Middle Income and age < 65 years- Ontario 0.803 0.616 1.047 
Middle Income and age < 65 years- New Brunswick 0.817 0.521 1.280 
Low Income and age ≥ 65 years 0.844 0.564 1.264 
Low Income and age ≥ 65 years- Ontario 0.842 0.542 1.310 
Low Income and age ≥ 65 years- New Brunswick  0.864 0.463 1.612 
Low Income and age < 65 years 0.783 0.516 1.187 
Low Income and age < 65 years- Ontario 0.796 0.505 1.256 
Low Income and age < 65 years- New Brunswick 0.697 0.349 1.394 
Diabetics which use insulin 0.864 0.519 1.440 
Diabetics that have been using insulin < 10 years 0.486 0.156 1.519 
Diabetics that have been using insulin ≥ 10 years 1.091 0.615 1.935 
Odds after removing seniors, respondents with 
cancer history, and low income class  
0.795 0.635 0.995 
Odds after removing Ontario seniors that denied 
having insurance 
0.738 0.604 0.902 
 
